[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 147
1. Ahlquist T, Lind GE, Costa VL, Meling GI, Vatn M, Hoff GS, Rognum TO, Skotheim RI, Thiis-Evensen E, Lothe RA: Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers. Mol Cancer; 2008;7:94
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene methylation profiles of normal mucosa, and benign and malignant colorectal tumors identify early onset markers.
  • BACKGROUND: Multiple epigenetic and genetic changes have been reported in colorectal tumors, but few of these have clinical impact.
  • This study aims to pinpoint epigenetic markers that can discriminate between non-malignant and malignant tissue from the large bowel, i.e. markers with diagnostic potential.
  • Possible CIMP tumors were identified by comparing the methylation profile with microsatellite instability (MSI), BRAF-, KRAS-, and TP53 mutation status.
  • RESULTS: The mean number of methylated genes per sample was 0.4 in normal colon mucosa from tumor-free individuals, 1.2 in mucosa from cancerous bowels, 2.2 in adenomas, and 3.9 in carcinomas.
  • The promoters of ADAMTS1, MAL, and MGMT were frequently methylated in benign samples as well as in malignant tumors, independent of microsatellite instability.
  • In contrast, normal mucosa samples taken from bowels without tumor were rarely methylated for the same genes.
  • CONCLUSION: Methylated ADAMTS1, MGMT, and MAL are suitable as markers for early tumor detection.
  • [MeSH-major] Biomarkers, Tumor / analysis. Colonic Neoplasms / genetics. Colonic Neoplasms / pathology. DNA Methylation. Early Detection of Cancer. Genes, Neoplasm. Intestinal Mucosa / metabolism
  • [MeSH-minor] Adenoma / genetics. Adult. Aged. Aged, 80 and over. Cluster Analysis. DNA, Neoplasm / metabolism. Epigenesis, Genetic. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Microsatellite Instability. Microsatellite Repeats / genetics. Middle Aged. Promoter Regions, Genetic. Sex Characteristics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9107-16 [17909015.001]
  • [Cites] PLoS Genet. 2007 Sep;3(9):1709-23 [17892325.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18654-9 [18003927.001]
  • [Cites] Surg Oncol. 2007 Dec;16 Suppl 1:S7-9 [18023574.001]
  • [Cites] Int J Cancer. 2008 Jun 1;122(11):2429-36 [18240147.001]
  • [Cites] J Transl Med. 2008;6:13 [18346269.001]
  • [Cites] J Korean Med Sci. 2008 Apr;23(2):270-7 [18437011.001]
  • [Cites] Oncol Rep. 2008 Jun;19(6):1571-6 [18497967.001]
  • [Cites] Eur J Cancer. 2008 Jun;44(9):1290-301 [18486467.001]
  • [Cites] Nat Genet. 2000 Feb;24(2):132-8 [10655057.001]
  • [Cites] Cancer Res. 2001 Apr 15;61(8):3410-8 [11309301.001]
  • [Cites] Dig Liver Dis. 2001 May;33(4):372-88 [11432519.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Jul;10(7):799-803 [11440966.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9796-801 [11481438.001]
  • [Cites] Neoplasia. 2008 Jul;10(7):680-6, 2 p following 686 [18592002.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):136-42 [18542073.001]
  • [Cites] Am J Pathol. 2002 Mar;160(3):795-800 [11891178.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):285-91 [11896207.001]
  • [Cites] Am J Pathol. 2002 May;160(5):1823-30 [12000733.001]
  • [Cites] Annu Rev Genomics Hum Genet. 2002;3:101-28 [12142355.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):815-22 [12598316.001]
  • [Cites] J Clin Oncol. 2003 Mar 1;21(5):820-9 [12610180.001]
  • [Cites] Acta Neuropathol. 2003 Nov;106(5):479-85 [12904991.001]
  • [Cites] Lancet. 2004 Apr 17;363(9417):1283-5 [15094274.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3014-21 [15126336.001]
  • [Cites] Histol Histopathol. 2004 Jul;19(3):925-33 [15168355.001]
  • [Cites] Biochem Biophys Res Commun. 2004 Jul 9;319(4):1327-33 [15194513.001]
  • [Cites] Lab Invest. 2004 Jul;84(7):884-93 [15122305.001]
  • [Cites] Genes Chromosomes Cancer. 2004 Oct;41(2):117-24 [15287024.001]
  • [Cites] J Natl Cancer Inst. 2004 Aug 18;96(16):1208-19 [15316056.001]
  • [Cites] Int J Cancer. 2004 Nov 10;112(3):407-10 [15382065.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):846-53 [15386372.001]
  • [Cites] Int J Cancer. 2004 Dec 10;112(5):754-9 [15386381.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Apr;84(7):1997-2001 [3494249.001]
  • [Cites] Br J Cancer. 1991 Sep;64(3):475-80 [1911187.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1827-31 [1542678.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Cancer Res. 1998 Dec 1;58(23):5489-94 [9850084.001]
  • [Cites] Cancer Res. 1999 Feb 15;59(4):793-7 [10029064.001]
  • [Cites] Scand J Gastroenterol. 1999 Apr;34(4):414-20 [10365903.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Jul 20;96(15):8681-6 [10411935.001]
  • [Cites] Mol Cancer. 2004 Oct 11;3:28 [15476557.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1203-9 [15709190.001]
  • [Cites] J Natl Cancer Inst. 2005 Aug 3;97(15):1124-32 [16077070.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1317-9 [16174847.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 21;97(18):1330-8 [16174854.001]
  • [Cites] Am J Gastroenterol. 2005 Oct;100(10):2274-9 [16181380.001]
  • [Cites] Neoplasia. 2005 Aug;7(8):771-8 [16207479.001]
  • [Cites] Carcinogenesis. 2005 Dec;26(12):2078-85 [16033773.001]
  • [Cites] Nat Rev Genet. 2006 Jan;7(1):21-33 [16369569.001]
  • [Cites] Annu Rev Med. 2006;57:1-18 [16409133.001]
  • [Cites] Int J Cancer. 2006 Feb 15;118(4):924-31 [16108009.001]
  • [Cites] Genome Res. 2006 Feb;16(2):282-9 [16369045.001]
  • [Cites] Br J Cancer. 2006 Feb 27;94(4):593-8 [16421593.001]
  • [Cites] Diagn Mol Pathol. 2006 Mar;15(1):17-23 [16531764.001]
  • [Cites] Nat Genet. 2006 May;38(5):540-9 [16642018.001]
  • [Cites] Pathol Res Pract. 2006;202(6):415-24 [16675157.001]
  • [Cites] Nat Genet. 2006 Jul;38(7):787-93 [16804544.001]
  • [Cites] Oncol Rep. 2006 Aug;16(2):429-35 [16820927.001]
  • [Cites] J Gastroenterol Hepatol. 2006 Aug;21(8):1334-9 [16872319.001]
  • [Cites] Gut. 2006 Oct;55(10):1467-74 [16469793.001]
  • [Cites] Cancer Res. 2006 Nov 15;66(22):10664-70 [17090521.001]
  • [Cites] Cell Oncol. 2006;28(5-6):247-57 [17167178.001]
  • [Cites] Cell Oncol. 2006;28(5-6):259-72 [17167179.001]
  • [Cites] Hum Genet. 2007 Jan;120(5):701-11 [17024368.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):127-38 [17087942.001]
  • [Cites] World J Gastroenterol. 2007 Feb 14;13(6):950-4 [17352030.001]
  • [Cites] Crit Rev Oncog. 2006 Dec;12(3-4):273-87 [17425506.001]
  • [Cites] Gastroenterology. 2007 Apr;132(4):1631-2; author reply 1632 [17408629.001]
  • [Cites] Oncol Rep. 2007 Jun;17(6):1421-7 [17487400.001]
  • [Cites] Clin Cancer Res. 2007 Sep 1;13(17):5048-55 [17785556.001]
  • (PMID = 19117505.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2639620
  •  go-up   go-down


2. Lázár G, Paszt A, Simonka Z, Rokszin R, Abrahám S: [Laparoscopic surgery in colorectal tumors]. Magy Onkol; 2010 Jun;54(2):117-22
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Laparoscopic surgery in colorectal tumors].
  • The minimally invasive technique, by means of the undoubted advantages of the method, has become fully accepted in the surgical treatments of the most benign and functional diseases.
  • Today it has been proven that the laparoscopic technique is safely usable also in the surgical treatment of colorectal tumors.
  • The authors, analyzing their own and the international experiences, present the laparoscopic surgical treatment of colorectal tumors.
  • Seventy-four patients were treated with laparoscopic-assisted colorectal intestinal resection in the Department of Surgery of the University of Szeged between January 1, 2005 and December 31, 2008.
  • The surgical indication was neoplastic colorectal lesion in 40 cases.
  • The histological processes of specimens justified tumor-free oral, aboral and circumferential resection in all cases.
  • Summarizing our own and international experiences it can be stated that the laparoscopic surgeries performed due to colorectal tumors are safe, and are also appropriate with respect to oncosurgery.
  • [MeSH-major] Colorectal Neoplasms / surgery. Digestive System Surgical Procedures / methods. Laparoscopy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colectomy / methods. Female. Humans. Hungary. Male. Middle Aged. Minimally Invasive Surgical Procedures / methods. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20576587.001).
  • [ISSN] 0025-0244
  • [Journal-full-title] Magyar onkologia
  • [ISO-abbreviation] Magy Onkol
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  •  go-up   go-down


3. Pesta M, Holubec L Jr, Topolcan O, Cerna M, Rupert K, Holubec LS, Treska V, Kormunda S, Elgrova L, Finek J, Cerny R: Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples. Anticancer Res; 2005 Sep-Oct;25(5):3387-91
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
  • BACKGROUND: An essential step in the process of tumor invasion and metastasis involves the degradation of tissue barriers in the extracellular matrix (ECM), particularly in the basal membrane (BM).
  • Matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs), in particular MMP-2, MMP-7, TIMP-1 and TIMP-2, play an important role in the process of ECM and BM degradation in connection with tumor invasion.
  • The aim of our study was to assess the levels of MMP-2, MMP-7, TIMP-1 and TIMP-2 mRNA expression in colorectal carcinoma tissue samples and to correlate them with the stage of the disease.
  • PATIENTS AND METHODS: The study included samples of tumor tissue of 38 patients with colorectal carcinoma and samples of tissue of 11 patients with benign disease.
  • RESULTS: The levels of mRNA expression of MMP-2, MMP-7 and TIMP-1 were significantly higher in tumor tissue samples that in the control tissue (p<0.0005, p<0.0007 and p<0.0004).
  • In addition the presence of mRNA MMP-2, MMP-7, TIMP-1 and TIMP-2 in tumor tissue samples in these parameters was significantly higher than in the control tissue (p<0.003, p<0.0001, p<0.0001 and p<0.05).
  • CONCLUSION: This pilot study demonstrated that a significant difference in the level and in the presence of mRNA MMP-2, MMP-7 and TIMP-1 expressions between tumor colorectal and control colorectal tissues might be helpful for the prognosis of colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / enzymology. Matrix Metalloproteinase 2 / biosynthesis. Matrix Metalloproteinase 7 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-2 / biosynthesis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Middle Aged. Neoplasm Staging. Polymerase Chain Reaction. RNA, Messenger / biosynthesis. RNA, Messenger / genetics

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101153.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1; 127497-59-0 / Tissue Inhibitor of Metalloproteinase-2; EC 3.4.24.23 / Matrix Metalloproteinase 7; EC 3.4.24.24 / Matrix Metalloproteinase 2
  •  go-up   go-down


Advertisement
4. Brozovich M, Read TE, Salgado J, Akbari RP, McCormick JT, Caushaj PF: Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution. Surg Endosc; 2008 Feb;22(2):506-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colectomy for apparently benign colorectal neoplasia: A word of caution.
  • PURPOSE: Endoscopically unresectable apparently benign colorectal polyps are considered by some surgeons as ideal for their early laparoscopic colectomy experience.
  • (1) a substantial fraction of patients undergoing laparoscopic colectomy for apparently benign colorectal neoplasia will have adenocarcinoma on final pathology; and (2) in our practice, we perform an adequate laparoscopic oncological resection for apparently benign polyps as evidenced by margin status and nodal retrieval.
  • METHODS: Data from a consecutive series of patients undergoing laparoscopic colectomy (on an intention-to-treat basis) for endoscopically unresectable neoplasms with benign preoperative histology were retrieved from a prospective database and supplemented by chart review.
  • The median nodal harvest was 12 and all resection margins were free of neoplasm.
  • Mean diameter of benign tumors was 3.2 cm (range 0.5-10.0cm) versus 3.9cm (range 1.5-7.5cm) for adenocarcinomas (p = 0.189, t - test).
  • CONCLUSION: A substantial fraction of endoscopically unresectable colorectal neoplasms with benign histology on initial biopsy will harbor invasive adenocarcinoma, some of advanced stage.
  • This finding supports the practice of performing oncological resection for all patients with endoscopically unresectable neoplasms of the colorectum.
  • [MeSH-major] Adenocarcinoma / surgery. Colectomy / methods. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704872.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


5. Seo GJ, Sohn DK, Han KS, Hong CW, Kim BC, Park JW, Choi HS, Chang HJ, Oh JH: Recurrence after endoscopic piecemeal mucosal resection for large sessile colorectal polyps. World J Gastroenterol; 2010 Jun 14;16(22):2806-11
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recurrence after endoscopic piecemeal mucosal resection for large sessile colorectal polyps.
  • AIM: To evaluate the safety and outcomes of endoscopic piecemeal mucosal resection (EPMR) for large sessile colorectal polyps.
  • METHODS: The patients enrolled in this study were 47 patients with 50 large sessile polyps (diameter, 2 cm or greater) who underwent EPMR using a submucosal saline injection technique between December 2002 and October 2005.
  • Of 50 polyps identified, 34 (68%) were benign and 16 (32%) were malignant.
  • The recurrence rate after EPMR was 3.1% for benign polyps and 33.3% for malignant polyps (P < 0.05).
  • [MeSH-major] Colonic Polyps / pathology. Colonic Polyps / surgery. Endoscopy, Gastrointestinal / methods. Intestinal Mucosa / pathology. Neoplasm Recurrence, Local / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastrointest Endosc. 2000 Jun;51(6):697-700 [10840302.001]
  • [Cites] J Gastroenterol Hepatol. 2010 Jan;25(1):84-9 [19793173.001]
  • [Cites] Endoscopy. 2003 Mar;35(3):212-8 [12584639.001]
  • [Cites] Dis Colon Rectum. 2003 Mar;46(3):340-8 [12626909.001]
  • [Cites] Endoscopy. 2003 Aug;35(8):S41-4 [12929053.001]
  • [Cites] Gut. 2004 Apr;53(4):568-72 [15016753.001]
  • [Cites] Gastrointest Endosc. 2004 Aug;60(2):234-41 [15278051.001]
  • [Cites] Am J Gastroenterol. 1977 May;67(5):430-8 [900105.001]
  • [Cites] Gastrointest Endosc. 1984 Feb;30(1):18-20 [6706083.001]
  • [Cites] Gastrointest Endosc. 1991 Mar-Apr;37(2):128-32 [2032596.001]
  • [Cites] Gastrointest Endosc. 1992 May-Jun;38(3):303-9 [1607080.001]
  • [Cites] Gastroenterology. 1997 Jan;112(1):24-8 [8978338.001]
  • [Cites] Gastrointest Endosc. 1999 Jun;49(6):731-5 [10343218.001]
  • [Cites] Tech Coloproctol. 2004 Dec;8 Suppl 2:s283-90 [15666108.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):34-41 [16012932.001]
  • [Cites] CA Cancer J Clin. 2006 May-Jun;56(3):143-59; quiz 184-5 [16737947.001]
  • [Cites] Dig Dis Sci. 2007 Mar;52(3):840-4 [17253129.001]
  • [Cites] Gastrointest Endosc. 2007 Jul;66(1):100-7 [17591481.001]
  • [Cites] Gastroenterol Clin North Am. 2008 Mar;37(1):229-51, ix [18313548.001]
  • [Cites] World J Gastroenterol. 2008 Apr 21;14(15):2364-9 [18416463.001]
  • [Cites] World J Gastroenterol. 2008 Jul 21;14(27):4289-95 [18666315.001]
  • [Cites] Gastrointest Endosc. 2008 Sep;68(3):615 [18760188.001]
  • [Cites] J Gastroenterol. 2008;43(9):641-51 [18807125.001]
  • [Cites] Surg Endosc. 2010 Feb;24(2):343-52 [19517168.001]
  • [Cites] Br J Surg. 2002 Aug;89(8):1020-4 [12153628.001]
  • (PMID = 20533602.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2883138
  •  go-up   go-down


6. De Chiara L, Rodríguez-Piñeiro AM, Rodríguez-Berrocal FJ, Cordero OJ, Martínez-Ares D, Páez de la Cadena M: Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas. BMC Cancer; 2010;10:333
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serum CD26 is related to histopathological polyp traits and behaves as a marker for colorectal cancer and advanced adenomas.
  • BACKGROUND: Serum CD26 (sCD26) levels were previously found diminished in colorectal cancer (CRC) patients compared to healthy donors, suggesting its potential utility for early diagnosis.
  • Patients were diagnosed as having no colorectal pathology, non-inflammatory or inflammatory bowel disease, polyps (hyperplastic, non-advanced and advanced adenomas) or CRC.
  • RESULTS: At a 460 ng/mL cut-off, the sCD26 has a sensitivity and specificity of 81.8% (95% CI, 64.5-93.0%) and 72.3% (95% CI, 65.0-77.2%) for CRC regarding no or benign colorectal pathology.
  • CONCLUSIONS: Our preliminary results show that measurement of the sCD26 is a non-invasive and reasonably sensitive assay, which could be combined with others such as the faecal occult blood test for the early diagnosis and screening of CRC and advanced adenomas.
  • [MeSH-major] Adenoma / blood. Biomarkers, Tumor / blood. Colorectal Neoplasms / blood. Dipeptidyl Peptidase 4 / blood. Polyps / metabolism. Polyps / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Colonoscopy. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Sensitivity and Specificity. Survival Rate. Young Adult

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Cancer. 2000 Nov;83(9):1139-46 [11027426.001]
  • [Cites] Aliment Pharmacol Ther. 2010 Feb 15;31(4):523-33 [19925498.001]
  • [Cites] N Engl J Med. 2001 Aug 23;345(8):555-60 [11529208.001]
  • [Cites] Scand J Immunol. 2001 Sep;54(3):249-64 [11555388.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2001 Nov;10(11):1165-8 [11700264.001]
  • [Cites] Am J Gastroenterol. 2002 Dec;97(12):3186-94 [12492209.001]
  • [Cites] Gastroenterology. 2003 Mar;124(3):608-14 [12612899.001]
  • [Cites] Eur J Cell Biol. 2003 Feb;82(2):53-73 [12647932.001]
  • [Cites] Cancer Metastasis Rev. 2003 Jun-Sep;22(2-3):259-69 [12785000.001]
  • [Cites] Dis Markers. 2003-2004;19(6):267-72 [15258327.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] N Engl J Med. 1993 May 13;328(19):1365-71 [8474513.001]
  • [Cites] N Engl J Med. 1993 Dec 30;329(27):1977-81 [8247072.001]
  • [Cites] N Engl J Med. 1996 Jan 18;334(3):155-9 [8531970.001]
  • [Cites] Lancet. 1996 Nov 30;348(9040):1472-7 [8942775.001]
  • [Cites] N Engl J Med. 2004 Dec 23;351(26):2704-14 [15616205.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):66-73 [16012935.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] Am J Gastroenterol. 2006 Feb;101(2):343-50 [16454841.001]
  • [Cites] Cancer. 2006 Oct 1;107(7):1624-33 [16933324.001]
  • [Cites] Cancer Res. 2007 Jun 15;67(12):5600-5 [17575123.001]
  • [Cites] J Natl Cancer Inst. 2007 Oct 3;99(19):1462-70 [17895475.001]
  • [Cites] Int J Cancer. 2008 Mar 15;122(6):1357-67 [18033685.001]
  • [Cites] Clin Cancer Res. 2008 Mar 1;14(5):1349-54 [18316554.001]
  • [Cites] CA Cancer J Clin. 2008 May-Jun;58(3):161-79 [18443206.001]
  • [Cites] World J Gastroenterol. 2008 May 7;14(17):2662-9 [18461651.001]
  • [Cites] Gastroenterology. 2008 May;134(5):1570-95 [18384785.001]
  • [Cites] Am J Gastroenterol. 2008 Jun;103(6):1541-9 [18479499.001]
  • [Cites] Int J Colorectal Dis. 2008 Apr;23(4):383-7 [18193432.001]
  • [Cites] Int J Colorectal Dis. 2009 Mar;24(3):275-81 [18979105.001]
  • [Cites] BMC Bioinformatics. 2009;10:209 [19586526.001]
  • [Cites] Dis Markers. 2009;27(6):311-6 [20075514.001]
  • [Cites] Oncology. 2000 Nov;59(4):310-6 [11096343.001]
  • (PMID = 20584285.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.4.14.5 / Dipeptidyl Peptidase 4
  • [Other-IDs] NLM/ PMC2912863
  •  go-up   go-down


7. Tsafrir D, Bacolod M, Selvanayagam Z, Tsafrir I, Shia J, Zeng Z, Liu H, Krier C, Stengel RF, Barany F, Gerald WL, Paty PB, Domany E, Notterman DA: Relationship of gene expression and chromosomal abnormalities in colorectal cancer. Cancer Res; 2006 Feb 15;66(4):2129-37
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship of gene expression and chromosomal abnormalities in colorectal cancer.
  • In this work, three types of array-generated data (expression, single nucleotide polymorphism, and comparative genomic hybridization) were collected from a large set of colon cancer patients at various stages of the disease.
  • We show that across many large regions of the genome, changes in expression level are correlated with alterations in DNA content.
  • Often, large chromosomal segments, containing multiple genes, are transcriptionally affected in a coordinated way, and we show that the underlying mechanism is a corresponding change in DNA content.
  • Indeed, particular chromosomal regions are frequently gained and overexpressed (e.g., 7p, 8q, 13q, and 20q) or lost and underexpressed (e.g., 1p, 4, 5q, 8p, 14q, 15q, and 18) in primary colon tumors, making it likely that these changes favor tumorigenicity.
  • Furthermore, we show that these aberrations are absent in normal colon mucosa, appear in benign adenomas (albeit only in a small fraction of the samples), become more frequent as disease advances, and are found in the majority of metastatic samples.
  • [MeSH-major] Chromosome Aberrations. Colorectal Neoplasms / genetics
  • [MeSH-minor] Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Carcinoma / genetics. Carcinoma / metabolism. Carcinoma / pathology. Chromosomes, Human, Pair 20 / genetics. DNA, Neoplasm / genetics. Gene Dosage. Gene Expression Profiling. Humans. Liver Neoplasms / genetics. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16489013.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01-CA65930
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm
  •  go-up   go-down


8. Hedrick TL, Galloway RP, McElearney ST, Smith RL, Ledesma EJ, Wilson WH, Sawyer RG, Friel CM, Foley EF: Screening practices of patients presenting for resection of a colorectal neoplasm. Am Surg; 2006 Jan;72(1):89-95
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening practices of patients presenting for resection of a colorectal neoplasm.
  • Multiple studies demonstrate the efficacy of colorectal cancer (CRC) screening in patients over 50 years of age.
  • The objective of this study was to identify the CRC screening practices at two institutions and determine the relationship between screening and pathologic stage for patients presenting with a colorectal neoplasm.
  • This study, conducted at the University of Virginia (UVA) Health System and the Salem Veterans Affairs Medical Center (VAMC) between October 30, 2000, and September 1, 2004, included 198 patients > or = 50 years who presented for resection of a primary colorectal neoplasm.
  • Ninety-one per cent of patients with benign polyps had been screened prior to diagnosis, compared with 72 per cent of patients with stage I and II cancer and 54 per cent of patients with stage III and IV cancer (P < 0.05).
  • CRC screening facilitates diagnosis at an early stage.
  • [MeSH-major] Colectomy. Colorectal Neoplasms. Mass Screening / methods
  • [MeSH-minor] Aged. Colonoscopy. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16494194.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


9. Uner A, Ebinc FA, Akyurek N, Unsal D, Mentes BB, Dursun A: Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma. Exp Oncol; 2005 Sep;27(3):225-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor, c-erbB-2 and c-erbB-3 expression in colorectal adenoma and adenocarcinoma.
  • AIM: To analyze vascular endothelial growth factor (VEGF), c-erbB-2 and c-erbB-3 expression and to evaluate their relation to clinicopathologic parameters and pathogenesis of colorectal carcinoma.
  • METHODS: Sections of adenoma, intramucosal carcinoma and adenocarcinoma were evaluated by immunohistochemistry in 85 malignant and 37 benign colorectal neoplasms for the expression of VEGF, c-erbB-2 and c-erbB-3 considering clinicopathological variables.
  • RESULTS: VEGF was detected in comparable percentages of all neoplasm types while c-erbB-2 expression was detectable more frequently in adenoma than adenocarcinoma cases (65% vs 43%).
  • Except for the correlation of c-erbB-3 expression with Dukes' staging, there was no correlation between the studied markers and grade of differentiation, Dukes' stage and localization of colorectal adenocarcinoma. c-erbB-3 expression was seen more frequently in tubular adenomas, while c-erbB-2 expression was higher in tubulovillous and villous types.
  • CONCLUSION: These results suggest that VEGF, c-erbB-2, c-erbB-3 expression does not have prognostic value in colorectal cancer.
  • [MeSH-major] Adenocarcinoma / genetics. Adenoma / genetics. Colorectal Neoplasms / genetics. Receptor, ErbB-2 / biosynthesis. Receptor, ErbB-3 / biosynthesis. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16244586.001).
  • [ISSN] 1812-9269
  • [Journal-full-title] Experimental oncology
  • [ISO-abbreviation] Exp. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Vascular Endothelial Growth Factor A; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.10.1 / Receptor, ErbB-3
  •  go-up   go-down


10. Consolo P, Luigiano C, Pellicano R, Ferrara F, Giacobbe G, Morace C, Pallio S, Tortora A, Melita G, Bassi M, D'Imperio N, Alibrandi A, Familiari L: Endoscopic resection as a safe and effective technique for treatment of pedunculated and non-pedunculated benign-appearing colorectal neoplasms measuring 40 mm or more in size. Minerva Med; 2010 Oct;101(5):311-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic resection as a safe and effective technique for treatment of pedunculated and non-pedunculated benign-appearing colorectal neoplasms measuring 40 mm or more in size.
  • AIM: The aim of this paper was to evaluate the outcome of endoscopic resection (ER) for pedunculated and non-pedunculated colorectal neoplasms exceeding 4 cm in size.
  • METHODS: All patients with a colorectal neoplasms measuring 4 cm or more, who underwent ER at our institution between January 1996 and December 2008 were included in the study.
  • The mean neoplasms size was 48.2±12.5 mm.
  • There were 32 sessile, 26 flat and 9 pedunculated neoplasms.
  • The most frequent type of neoplasm was villous adenoma (76.1%).
  • CONCLUSION: ER is a safe and effective procedure for removing benign appearing very large colorectal neoplasms.
  • [MeSH-major] Colonic Polyps / surgery. Colonoscopy. Colorectal Neoplasms / surgery
  • [MeSH-minor] Aged. Female. Follow-Up Studies. Hemostasis, Surgical / methods. Humans. Male. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Postoperative Hemorrhage / etiology. Postoperative Hemorrhage / therapy. Tumor Burden

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Minerva Med. 2011 Apr;102(2):XV. Giuseppinella, M [corrected to Melita, G]
  • (PMID = 21048553.001).
  • [ISSN] 0026-4806
  • [Journal-full-title] Minerva medica
  • [ISO-abbreviation] Minerva Med.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


11. Pillinger SH, Monson JR: Laparoscopy for colorectal malignancy. Dig Surg; 2005;22(1-2):34-40
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopy for colorectal malignancy.
  • Laparoscopy for colorectal pathology is technically demanding with a steep learning curve.
  • In expert hands, there is no doubt that there is a place for laparoscopy in the operative armamentarium for the treatment of benign disease.
  • The evidence available suggests that laparoscopic resection is a feasible and appropriate option for the treatment of colorectal carcinoma.
  • [MeSH-major] Colorectal Neoplasms / surgery. Laparoscopy
  • [MeSH-minor] Anastomosis, Surgical. Clinical Competence. Humans. Neoplasm Staging. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15838169.001).
  • [ISSN] 0253-4886
  • [Journal-full-title] Digestive surgery
  • [ISO-abbreviation] Dig Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Number-of-references] 82
  •  go-up   go-down


12. Gelos M, Hinderberger D, Welsing E, Belting J, Schnurr K, Mann B: Analysis of albumin fatty acid binding capacity in patients with benign and malignant colorectal diseases using electron spin resonance (ESR) spectroscopy. Int J Colorectal Dis; 2010 Jan;25(1):119-27
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of albumin fatty acid binding capacity in patients with benign and malignant colorectal diseases using electron spin resonance (ESR) spectroscopy.
  • INTRODUCTION: In colorectal cancer (CRC), no biological marker is known that could serve both as a marker for detection and prognosis.
  • OBJECTIVE: The aim of this study was to examine whether the FA binding to albumin is detectably and significantly altered in CRC patients when compared with patients having benign colorectal diseases.
  • MATERIALS AND METHODS: One hundred four patients operatively or endoscopically treated for CRC, sigmoid diverticulitis, or a colorectal adenoma were examined before procedure.
  • RESULTS AND DISCUSSIONS: Patients with CRC showed significantly lower DR values (DR, -0.09 +/- 0.98 vs. 0.61 +/- 1.43) than patients with benign colorectal diseases, consistent with a change of conformation and transport function of albumin in CRC.
  • Within the CRC group, with advanced tumor stage, the difference in DR values increased.
  • Furthermore, a correlation with advanced tumor stage can be established.
  • [MeSH-major] Colorectal Neoplasms / metabolism. Electron Spin Resonance Spectroscopy / methods. Fatty Acids / metabolism. Serum Albumin / metabolism
  • [MeSH-minor] Aged. Demography. Endoscopy. Female. Humans. Male. Neoplasm Staging. Postoperative Care. Preoperative Care. Protein Binding

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19644694.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Fatty Acids; 0 / Serum Albumin
  •  go-up   go-down


13. Kume K, Murata I, Yoshikawa I, Yamasaki M, Kanda K, Otsuki M: Endoscopic piecemeal mucosal resection of large colorectal tumors. Hepatogastroenterology; 2005 Mar-Apr;52(62):429-32
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic piecemeal mucosal resection of large colorectal tumors.
  • BACKGROUND/AIMS: Since endoscopic en bloc resection of large and sessile tumors is technically difficult, endoscopic en bloc piecemeal mucosal resection (EPMR) is usually chosen for resection of such tumors.
  • Tumors resected by EPMR are, however, difficult to evaluate histologically.
  • METHODOLOGY: We removed 30 large colorectal tumors in 30 patients by EPMR between 1992-2000.
  • Patients in whom no residual tumor was found by both endoscopic and histologic examination were considered to be "cured".
  • RESULTS: Histological examination of the resected tumor tissues revealed malignancy in 43.3% (13/30).
  • Three patients had invasive malignant tumors and underwent surgery.
  • Following complete endoscopic resection, recurrences were observed in 2 patients with benign tumors, which were resected by additional endoscopic resection.
  • All patients including the two with non-invasive malignant tumors remain free from recurrence during a mean follow-up period of 45.2 months (range, 3-104 months).
  • CONCLUSIONS: EPMR of benign or non-invasive large malignant tumors is a safe and effective procedure.
  • Complete excision of large, sessile and non-invasive tumors is possible, although complete removal by EPMR cannot be verified histologically.
  • [MeSH-major] Adenoma / surgery. Carcinoma / surgery. Colorectal Neoplasms / surgery. Endoscopy, Digestive System / methods. Intestinal Mucosa / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816450.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


14. Regöly-Mérei A, Bereczky M, Arató G, Telek G, Pallai Z, Lugasi A, Antal M: [Nutritional and antioxidant status of colorectal cancer patients]. Orv Hetil; 2007 Aug 12;148(32):1505-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nutritional and antioxidant status of colorectal cancer patients].
  • INTRODUCTION: Oxidative stress is one of the risk factors of colorectal carcinogenesis.
  • In inflammatory reactions the activated leucocytes product mutagenic and mitogenic free radicals, hereby promoting tumor formation.
  • AIM: Evaluation of some parameters of antioxidant and nutritional status in patients with benign or malignant colorectal neoplasm.
  • RESULTS: In patients with malignant tumor the dietary fiber, folate and vitamin A intake was under the optimal level, and the serum prealbumin concentration was lower than in patients with benign lesion.
  • CONCLUSIONS: The insufficient folate and vitamin A intake, the high incidence of overweight and obesity, and the abnormal values of the biomarkers of antioxidant status observed in the study groups seem to support the correlation between colorectal tumor, nutritional and antioxidant status.
  • [MeSH-major] Adenoma / blood. Antioxidants / metabolism. Carcinoma / blood. Colorectal Neoplasms / blood. Free Radical Scavengers / blood. Nutritional Status

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. MALONALDEHYDE .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. VITAMIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17675278.001).
  • [ISSN] 0030-6002
  • [Journal-full-title] Orvosi hetilap
  • [ISO-abbreviation] Orv Hetil
  • [Language] hun
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Hungary
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Biomarkers; 0 / Free Radical Scavengers; 0 / Prealbumin; 11103-57-4 / Vitamin A; 4Y8F71G49Q / Malondialdehyde; 935E97BOY8 / Folic Acid; EC 1.11.1.9 / Glutathione Peroxidase
  •  go-up   go-down


15. Øgreid D, Hamre E: Stool DNA analysis detects premorphological colorectal neoplasia: a case report. Eur J Gastroenterol Hepatol; 2007 Aug;19(8):725-7
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stool DNA analysis detects premorphological colorectal neoplasia: a case report.
  • Colorectal cancers usually develop from benign adenomas in a lengthy period of 5-10 years.
  • Our patient did not present any signs or symptoms of colorectal disease during his two visits to the endoscopist.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. DNA, Neoplasm / analysis. Feces / chemistry. Precancerous Conditions / diagnosis
  • [MeSH-minor] Colonic Polyps / diagnosis. Genetic Markers. Humans. Male. Middle Aged. Mutation. Neoplastic Syndromes, Hereditary / diagnosis. Proto-Oncogene Proteins / genetics. ras Proteins / genetics

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17625445.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Genetic Markers; 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 3.6.5.2 / ras Proteins
  •  go-up   go-down


16. Bettstetter M, Woenckhaus M, Wild PJ, Rümmele P, Blaszyk H, Hartmann A, Hofstädter F, Dietmaier W: Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer. J Pathol; 2005 Apr;205(5):606-14
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Elevated nuclear maspin expression is associated with microsatellite instability and high tumour grade in colorectal cancer.
  • In this study, expression of maspin was analysed in 41 colorectal carcinomas with high-frequency microsatellite instability (MSI-H) and 159 microsatellite stable colorectal cancers (MSS/MSI-L) by immunohistochemistry (IHC) and partly by relative quantitative real-time RT-PCR and western blot analyses.
  • Significant upregulation of maspin expression was found in MSI-H tumours compared to both MSS/MSI-L tumours and matched benign colonic mucosa.
  • These findings provide new insights into the role of maspin in colorectal cancer progression and may be useful for diagnosis and treatment strategies.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Colorectal Neoplasms / metabolism. Microsatellite Repeats. Neoplasm Proteins / metabolism. Serpins / metabolism
  • [MeSH-minor] Blotting, Western. Cell Nucleus / metabolism. CpG Islands. Cytoplasm / metabolism. DNA Methylation. DNA, Neoplasm / genetics. Genes, Tumor Suppressor. Humans. Neoplasm Invasiveness. Neoplasm Staging. Promoter Regions, Genetic. RNA, Neoplasm / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Transcription, Genetic

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15714592.001).
  • [ISSN] 0022-3417
  • [Journal-full-title] The Journal of pathology
  • [ISO-abbreviation] J. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Neoplasm Proteins; 0 / RNA, Neoplasm; 0 / SERPIN-B5; 0 / Serpins
  •  go-up   go-down


17. Shen C, Hu L, Xia L, Li Y: Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients. Jpn J Clin Oncol; 2008 Nov;38(11):770-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantitative real-time RT-PCR detection for survivin, CK20 and CEA in peripheral blood of colorectal cancer patients.
  • OBJECTIVE: To establish a sensitive method for the early detection of circulating tumor cells (CTCs) in peripheral blood (PB) of colorectal cancer (CRC) patients.
  • METHODS: PB samples were collected from 156 CRC patients, 40 benign colorectal disease patients, 40 healthy individuals and 45 patients with other solid tumors.
  • The expression of the three mRNAs in CRC patients was significantly higher than that in benign control and healthy volunteers, and the expression of survivin and CK20 was not significantly higher than that of patients with other solid tumors.
  • However, the expression of CEA mRNA was significantly higher than that of patients with other solid tumors.
  • [MeSH-major] Carcinoembryonic Antigen / blood. Colorectal Neoplasms / blood. Colorectal Neoplasms / diagnosis. Microtubule-Associated Proteins / blood. Neoplasm Proteins / blood. Neoplastic Cells, Circulating / chemistry. RNA, Messenger / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. Cell Line, Tumor. Female. Humans. Inhibitor of Apoptosis Proteins. Keratin-20 / blood. Keratin-20 / genetics. Leukocytes, Mononuclear / chemistry. Leukocytes, Mononuclear / cytology. Male. Middle Aged. Molecular Sequence Data. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18845519.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Carcinoembryonic Antigen; 0 / Inhibitor of Apoptosis Proteins; 0 / KRT20 protein, human; 0 / Keratin-20; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / RNA, Messenger
  •  go-up   go-down


18. Brent A, Talbot R, Coyne J, Nash G: Should indeterminate lung lesions reported on staging CT scans influence the management of patients with colorectal cancer? Colorectal Dis; 2007 Nov;9(9):816-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should indeterminate lung lesions reported on staging CT scans influence the management of patients with colorectal cancer?
  • OBJECTIVE: The aim of this study was to determine the significance of indeterminate lung lesions reported from staging CT scans on patients with colorectal cancer.
  • The tumour, node, metastasis (TNM) stage of these patients was recorded together with any follow-up scan reports or multidisciplinary team (MDT) discussions regarding these lesions.
  • In 19, the indeterminate lesions were unchanged and were therefore downgraded to benign lesions.
  • Indeterminate lung lesions are not a reason to delay surgery for colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / therapy. Lung / pathology. Lung / radiography. Lung Neoplasms / secondary
  • [MeSH-minor] Humans. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Neoplasm Staging. Tomography, Spiral Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17931171.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Benedix F, Köckerling F, Lippert H, Scheidbach H: Laparoscopic resection for endoscopically unresectable colorectal polyps: analysis of 525 patients. Surg Endosc; 2008 Dec;22(12):2576-82
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic resection for endoscopically unresectable colorectal polyps: analysis of 525 patients.
  • However, the high rate of malignant transformation despite initially benign histology continues to be a problem.
  • METHODS: Within the framework of a prospective multicenter observational study, all patients with adenomatous polyps unsuitable for endoscopic removal and with benign histology were investigated.
  • In addition to an analysis of the perioperative course and the definitive histology, the overall and disease-free survival rates of patients with malignant transformation of colorectal adenomas were also calculated.
  • In the elderly patient presenting with comorbidities limited resection aiming to minimize surgical trauma in potentially benign disease may be considered.
  • [MeSH-major] Adenocarcinoma / surgery. Adenomatous Polyps / surgery. Colonic Polyps / surgery. Colorectal Neoplasms / surgery. Laparoscopy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Colectomy / methods. Colonoscopy. Disease Progression. Disease-Free Survival. Female. Humans. Laparotomy / statistics & numerical data. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Postoperative Complications / epidemiology. Prospective Studies. Young Adult

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18626704.001).
  • [ISSN] 1432-2218
  • [Journal-full-title] Surgical endoscopy
  • [ISO-abbreviation] Surg Endosc
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


20. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG: Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management. Ann Surg; 2010 Jan;251(1):64-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: implications for management.
  • OBJECTIVE: To estimate the frequency of extrapancreatic neoplasms in patients with IPMN compared with those with ductal pancreatic cancer and a general referral population.
  • SUMMARY BACKGROUND DATA: Several studies have reported an increased risk of extrapancreatic neoplasms in patients with IPMN, but these studies focused only on those patients who underwent resection and excluded those patients treated nonoperatively.
  • Two control groups consisting of Group 1-patients with a diagnosis of ductal pancreatic adenocarcinoma (1:1) and Group 2-a general referral population (3:1) were matched for gender and age at diagnosis, year of registration, and residence.
  • Logistic regression was used to assess the risk of a diagnosis of extrapancreatic neoplasms among cases versus controls.
  • The proportion of IPMN patients having any extrapancreatic neoplasm diagnosed before or coincident to the index date was 52% (95% CI, 47%-56%), compared with 36% (95% CI, 32%-41%) in Group 1 (P < 0.001), and 43% (95% CI, 41%-46%) in Group 2 (P = 0.002).
  • Benign neoplasms most frequent in the IPMN group were colonic polyps (n = 114) and Barrett's neoplasia (n = 18).
  • The most common malignant neoplasms were nonmelanoma skin (n = 35), breast (n = 24), prostate (n = 24), colorectal cancers (n = 19), and carcinoid neoplasms (n = 6).
  • CONCLUSIONS: Patients with IPMN have increased risk of harboring extrapancreatic neoplasms.
  • [MeSH-major] Adenocarcinoma, Mucinous / therapy. Carcinoma, Pancreatic Ductal / therapy. Carcinoma, Papillary / therapy. Neoplasms, Multiple Primary / diagnosis. Pancreatic Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19858708.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / 1 UL1 RR024150
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  •  go-up   go-down


21. Inbar R, Greenberg R, Nir S, Shmueli E, Scornick Y, Avital S: [Three hundred laparoscopic colorectal operations--safety, levels of difficulty and survival]. Harefuah; 2010 Aug;149(8):498-502, 552, 551
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Three hundred laparoscopic colorectal operations--safety, levels of difficulty and survival].
  • INTRODUCTION: The accumulated data in recent years on the safety of laparoscopy in colorectal cancer patients encourage more surgeons to use this approach for different colorectal pathologies.
  • However, laparoscopic colorectal surgery consists of different heterogeneous complex procedures that necessitate extensive experience and laparoscopic surgical skills PURPOSE: To evaluate safety, levels of difficulty and oncological outcome in a consecutive series of patients that underwent elective laparoscopic colorectal surgery during a 5-year period.
  • METHODS: Evaluation of our prospective collected data of patients that underwent laparoscopic colorectal surgery during a 5-year period by our surgical team.
  • Indications for surgery included cancer (58%), benign polyps (16%), Crohn's disease (6%), diverticular disease (10%) and others (10%).
  • A total of 171 patients underwent operations for curable colorectal cancer.
  • CONCLUSIONS: Laparoscopic colorectal surgery is safe.
  • Immediate oncological results and 2-year survival in colorectal cancer patients, as demonstrated in our study, are adequate and comparable to the open approach.
  • The authors believe that adequate results in laparoscopic colorectal operations can be achieved by a dedicated laparoscopic colorectal team.
  • [MeSH-major] Colorectal Neoplasms / surgery. Intestinal Diseases / surgery. Laparoscopy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Elective Surgical Procedures / adverse effects. Elective Surgical Procedures / methods. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Postoperative Complications / etiology. Prospective Studies. Reoperation. Surgical Wound Infection / epidemiology. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21341427.001).
  • [ISSN] 0017-7768
  • [Journal-full-title] Harefuah
  • [ISO-abbreviation] Harefuah
  • [Language] heb
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


22. Ducreux M, Dromain C: [Non-invasive imaging tools in colorectal cancer]. Rev Prat; 2010 Oct 20;60(8):1071-3
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Non-invasive imaging tools in colorectal cancer].
  • Coloscanner is a new radiologic tool to determine if abnormalities of colon and especially neoplasms are present.
  • In colorectal neoplasm, it is now considered as essential for the diagnosis of unexplained raise of CEA levels, differential diagnosis between benign and malignant disease (especially for suspected local recurrence of rectal cancer), or preoperative staging in case of complex surgical strategies.
  • [MeSH-major] Colorectal Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21197735.001).
  • [ISSN] 0035-2640
  • [Journal-full-title] La Revue du praticien
  • [ISO-abbreviation] Rev Prat
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


23. Amosenko FA, Korchagina EL, Matveeva TI, Vaganov IuE, Vlasov SB, Poltavets NV, Veselov VV, Gar'kavtseva RF, Poliakov AV: [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients]. Genetika; 2010 May;46(5):700-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Mutation analysis of K-ras protooncogene in colorectal adenocarcinomas and polyps in Russian patients].
  • To estimate diagnostic value of K-ras mutations during cancer risk group formation, they were studied in the samples of sporadic carcinomas (n = 33) and malignant (n = 13) polyps of large intestine obtained during surgery or polypectomy.
  • Mutation frequency in carcinomas, benign and malignant polyps was 43, 49, and 69%, respectively.
  • In the healthy tissue of the large intestine, no changes in codons 12 and 13 in the K-ras gene were observed.
  • In patients with colorectal carcinoma the mutation frequency in the K-ras gene was not associated with disease onset age, location, and the extent of tumor differentiation while it was associated with the stage of tumor process.
  • The maximum mutation frequency was revealed in polyps of patients over 70 years of age as well as in the adenomas of villous histology and large size ((1 cm).
  • [MeSH-major] Adenocarcinoma / genetics. Colonic Polyps / genetics. Colorectal Neoplasms / genetics. DNA, Neoplasm / genetics. Genes, ras / genetics. Mutation

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20583607.001).
  • [ISSN] 0016-6758
  • [Journal-full-title] Genetika
  • [ISO-abbreviation] Genetika
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Codon; 0 / DNA, Neoplasm
  •  go-up   go-down


24. Yu YJ, Liu YD, Xu X, Ma XW: [Diagnostic significance of cytokeratin 19 and 20 expression on micrometastasis of colorectal cancer]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jan;12(1):48-51
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnostic significance of cytokeratin 19 and 20 expression on micrometastasis of colorectal cancer].
  • OBJECTIVE: To inquire into the diagnostic significance of cytokeratin 19(CK19) and cytokeratin 20(CK20) expression on hematogenous micrometastasis of colorectal cancer.
  • METHODS: Forty-four patients with colorectal cancer were collected as colorectal cancer groups, and another 18 patients treated with abdominal surgical operations because of benign diseases were collected as benign disease group.
  • RESULTS: There were no positive expression of CK19 and CK20 in the portal and peripheral blood of all the patients in benign disease group.
  • Of the colorectal cancer group, 34 patients(77.3%) appeared positive expressions of CK19 and/or CK20 in portal and peripheral blood, and there was significant difference in the expressions of CK19 and CK20 between the two groups(P<0.05).
  • Within the colorectal cancer group, the positive expression rates of CK19 and CK20 in peripheral blood were 36.4% and 52.3%, and the rates in portal blood were 59.1% and 72.7%.
  • The postoperative metastasis and recurrence rate of colorectal cancer in patients with positive expression of CK19 and CK20 in peripheral blood was 61.5%, which was significantly higher than that(25.0%) in patients with positive expression in portal blood only(P<0.05).
  • CONCLUSIONS: In patients with colorectal cancer, the expressions of CK19 and CK20, which are determined by RT-PCR in blood from portal and peripheral veins, are the sensitive and specific indexes for diagnosing hematogenous micrometastasis of the cancer.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Keratin-19 / blood. Keratin-20 / blood
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145504.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-19; 0 / Keratin-20
  •  go-up   go-down


25. Cserni G, Bori R, Sejben I: Vascular invasion demonstrated by elastic stain-a common phenomenon in benign granular cell tumors. Virchows Arch; 2009 Feb;454(2):211-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular invasion demonstrated by elastic stain-a common phenomenon in benign granular cell tumors.
  • Granular cell tumor is generally benign, but rare malignant cases have been documented.
  • Features of malignancy include necrosis, cellular spindling, vesicular nuclei with large nucleoli, increased mitotic activity, high nuclear to cytoplasmic ratio, and pleomorphism, but not vascular invasion.
  • Venous invasion was incidentally identified with the orcein elastic stain in an otherwise benign granular cell tumor (propositus case).
  • Four further benign granular cell tumors were also analyzed; venous invasion was discovered in three.
  • It is suggested that vascular invasion is not uncommon in granular cell tumors and should not lead to the classification of the tumor as malignant or atypical.
  • It is also suggested that some cases of vascular invasion identified by elastic stains in tumors such as colorectal carcinomas (where these stains are recommended for routine use) may also represent invasion of vascular structures without the propensity of metastasis.
  • [MeSH-major] Blood Vessels / pathology. Elastic Tissue / pathology. Granular Cell Tumor / pathology. Staining and Labeling / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Lymphatic Metastasis. Male. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19066954.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


26. Choi YJ, Park SH, Lee SS, Choi EK, Yu CS, Kim HC, Kim JC: CT colonography for follow-up after surgery for colorectal cancer. AJR Am J Roentgenol; 2007 Aug;189(2):283-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CT colonography for follow-up after surgery for colorectal cancer.
  • OBJECTIVE: The purpose of this article is to discuss the CT colonography (CTC) findings and the role of CTC for follow-up after curative surgery for colorectal cancer.
  • CONCLUSION: Contrast-enhanced CTC can be effective for surveillance for colorectal cancer recurrence after curative surgery because it enables simultaneous evaluation of distant abdominal metastasis, pericolic recurrence, intraluminal recurrence, and metachronous lesions.
  • The appearances of anastomotic recurrences at CTC overlap with those of more common inflammatory polyps and rare benign ulcers.
  • [MeSH-major] Colonography, Computed Tomographic / methods. Colorectal Neoplasms / radiography. Colorectal Neoplasms / surgery
  • [MeSH-minor] Colonic Polyps / radiography. Colonoscopy. Contrast Media. Humans. Neoplasm Recurrence, Local / radiography. Postoperative Complications / radiography. Time Factors

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17646452.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  • [Number-of-references] 13
  •  go-up   go-down


27. Cui M, Wang S, Ye YJ, Cui ZR, Ke Y: [Effect of tumor burden on differentiation of T lymphocytes in the peripheral blood of patients with colorectal cancer]. Zhonghua Yi Xue Za Zhi; 2007 Jan 2;87(1):16-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of tumor burden on differentiation of T lymphocytes in the peripheral blood of patients with colorectal cancer].
  • OBJECTIVE: To analyze the effect of tumor burden on the differentiation of T1 and T2 cells and its implication in patients with colorectal cancer.
  • METHODS: Peripheral venous blood samples were obtained from 20 patients with primary colorectal cancer before and 7 days after the operation, radical operation in 17 patients and palliative resection in 3 patients.
  • Twenty sex and age-matched patients with benign diseases treated in the same period were used as controls.
  • RESULTS: At the time of diagnosis, the percentage of T1 and T2 cells in the peripheral lymphocytes of the case group was lower significantly than that of the control group (P = 0.006, and P = 0.017).
  • After getting rid of the tumor burden, the percentage of T1 cells increased, however, not significantly (P > 0.05).
  • The percentages of T1 cell of the patients with the tumor > or = 5 cm and of the patients with poorly differentiated tumors were significantly lower than those of the patients with the tumor < 5 cm and of the patients with well or moderately differentiated tumors (P = 0.064, and P = 0.072).
  • The percentage of T1 cells in the patients with lymph node metastasis and stage III approximately IV tumor were lower significantly than those of the patients without lymph node metastasis and those with stage I approximately II tumor (P = 0.033 and P = 0.033).
  • No significant differences were found between the population of T1 cells and such factors as tumor size, serosa invasion, and distant metastasis.
  • CONCLUSION: Tumor load suppresses the differentiation of T1 and T2 cells in the patients with colorectal cancer significantly, and may be an important factor in the development of immunosuppression.
  • After getting rid of the tumor burden, the percentages of T1 and T2 increase in a short time, and the immunologic function is improved.
  • Determination of T1 may be helpful to indicate the prognosis of colorectal cancer.
  • [MeSH-major] Cell Differentiation / immunology. Colorectal Neoplasms / blood. Colorectal Neoplasms / pathology. T-Lymphocytes / cytology
  • [MeSH-minor] Aged. CD4-Positive T-Lymphocytes / cytology. CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / cytology. CD8-Positive T-Lymphocytes / immunology. Female. Flow Cytometry. Humans. Killer Cells, Natural / cytology. Killer Cells, Natural / immunology. Male. Middle Aged. Neoplasm Staging. Tumor Burden

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17403305.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


28. Wichmann MW, Hüttl TP, Winter H, Spelsberg F, Angele MK, Heiss MM, Jauch KW: Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study. Arch Surg; 2005 Jul;140(7):692-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunological effects of laparoscopic vs open colorectal surgery: a prospective clinical study.
  • HYPOTHESIS: Laparoscopy has become a popular approach for the surgical treatment of benign and even malignant colorectal diseases.
  • Several authors have reported better preserved immunity in patients undergoing laparoscopic compared with conventional colorectal surgery.
  • The present study addresses the hypothesis that specific and nonspecific immunity are differently affected by laparoscopic and conventional colorectal surgery.
  • PATIENTS: Seventy prospectively enrolled patients with colorectal diseases undergoing laparoscopic (n = 35) or open (n = 35) surgery.
  • The levels of B lymphocytes and T lymphocytes and helper T-cell counts and cytotoxic (suppressor) T-cell counts did not show significant differences after open or laparoscopic surgery.
  • These findings are important because a divergent effect on specific and nonspecific immunity of laparoscopic surgery for colorectal disease has not been reported before.
  • [MeSH-major] Colorectal Neoplasms / immunology. Colorectal Neoplasms / surgery. Immunity, Cellular / physiology. Laparoscopy / methods. Laparotomy / methods. Postoperative Complications / immunology
  • [MeSH-minor] Aged. Analysis of Variance. Biomarkers / blood. Female. Hospitals, University. Humans. Immunocompetence / physiology. Inflammation Mediators / analysis. Male. Middle Aged. Neoplasm Staging. Probability. Prognosis. Prospective Studies. Risk Assessment. Sensitivity and Specificity. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16027336.001).
  • [ISSN] 0004-0010
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Inflammation Mediators
  •  go-up   go-down


29. Singhi AD, Montgomery EA: Colorectal granular cell tumor: a clinicopathologic study of 26 cases. Am J Surg Pathol; 2010 Aug;34(8):1186-92
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal granular cell tumor: a clinicopathologic study of 26 cases.
  • Granular cell tumor (GCT) is commonly located in the subcutaneous tissue and oral cavity, and uncommon in the gastrointestinal tract, in which the majority arises in the esophagus with over-representation in African Americans (AA).
  • We report the clinicopathologic features of 1 of the largest series to date of colorectal GCTs.
  • We reviewed the clinical features of 26 colorectal GCTs seen at our institution between the years 1995 to 2009, which included 24 biopsies, 1 low anterior resection, and 1 colectomy.
  • The majority of colorectal GCT involved the right colon (19/26, 73%) ranging in size from 0.2 to 1.8 cm (mean 0.6 cm).
  • Most neoplasms were encountered on routine colonoscopy (14/24, 64%), however 3 patients presented with hematochezia, 3 with changing bowel habits, 2 with Crohn disease, 1 with diverticular disease, and 1 with appendicitis.
  • Of the 20 cases available for histologic review, the tumors were noted to either be infiltrative (12/20, 60%) or marginated (8/20, 40%) involving either the mucosa (7/20, 35%), submucosa (10/20, 50%), or both (3/20, 15%).
  • The microscopic features were similar to those of GCTs found elsewhere, but many of the neoplasms differed by displaying nuclear pleomorphism (8/20, 40%), lymphoid cuffs (9/20, 45%), and focal calcification (7/20, 35%).
  • On immunochemistry, 18 of the neoplasms were stained for S-100 and all cases showed positive staining.
  • Although infrequently found in the colorectum, colorectal GCT typically presents incidentally on routine colonoscopy and involves the right colon; it is not over-represented in AA patients.
  • GCTs can have both an infiltrative or marginated growth pattern with a subset displaying nuclear pleomorphism, a lymphoid cuff, focal calcification, and reactive mucosal surface changes, which in our experience, may lead to misdiagnosis on colorectal mucosal biopsies.
  • Although GCTs were benign tumors in this series, if incompletely excised regrowth of the lesion may occur and therefore, follow-up may be warranted.
  • [MeSH-major] Adenocarcinoma / pathology. Colon / pathology. Colorectal Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Biopsy. Colectomy. Colonoscopy. Female. Humans. Immunohistochemistry. Intestinal Mucosa / pathology. Male. Middle Aged. Neoplasm Invasiveness. Prognosis. S100 Proteins / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20661017.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


30. Pickhardt PJ, Kim DH, Meiners RJ, Wyatt KS, Hanson ME, Barlow DS, Cullen PA, Remtulla RA, Cash BD: Colorectal and extracolonic cancers detected at screening CT colonography in 10,286 asymptomatic adults. Radiology; 2010 Apr;255(1):83-8
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal and extracolonic cancers detected at screening CT colonography in 10,286 asymptomatic adults.
  • PURPOSE: To retrospectively determine the detection rates, clinical stages, and short-term patient survival for all unsuspected cancers identified at screening computed tomographic (CT) colonography, including both colorectal carcinoma (CRC) and extracolonic malignancies.
  • MATERIALS AND METHODS: From April 2004 through March 2008, prospective colorectal and extracolonic interpretation was performed in 10,286 outpatient adults (5388 men, 4898 women; mean age, 59.8 years) undergoing screening CT colonography at two centers in this institutional review board-approved, HIPAA-compliant study.
  • Benign neoplasms (including advanced colorectal adenomas), symptomatic lesions, and tumors without pathologic proof were excluded.
  • Extracolonic malignancies included renal cell carcinoma (n = 11), lung cancer (n = 8), non-Hodgkin lymphoma (n = 6), and a variety of other tumors (n = 11).
  • [MeSH-major] Colonography, Computed Tomographic. Colorectal Neoplasms / diagnostic imaging
  • [MeSH-minor] Adenoma / diagnostic imaging. Adenoma / pathology. Female. Humans. Kidney Neoplasms / diagnostic imaging. Kidney Neoplasms / pathology. Lung Neoplasms / diagnostic imaging. Lung Neoplasms / pathology. Lymphatic Metastasis. Lymphoma, Non-Hodgkin / diagnostic imaging. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Neoplasms, Multiple Primary / diagnostic imaging. Neoplasms, Multiple Primary / pathology. Radiographic Image Interpretation, Computer-Assisted. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] RSNA, 2010
  • (PMID = 20308446.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA144835
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


31. Belizon A, Balik E, Horst PK, Shantha Kumara HM, Nasar A, Whelan RL: Platelet-derived growth factor (subtype BB) is elevated in patients with colorectal carcinoma. Dis Colon Rectum; 2009 Jun;52(6):1166-71
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platelet-derived growth factor (subtype BB) is elevated in patients with colorectal carcinoma.
  • PURPOSE: Platelet-derived growth factor-BB plays a role in the development of vascular and lymphatic vessels in tumors.
  • In this study plasma levels of platelet-derived growth factor-BB were assessed preoperatively in patients with adenomas and colorectal cancer to determine whether platelet-derived growth factor-BB is a useful marker or prognostic indicator.
  • METHODS: Patients with adenomas and colorectal cancer undergoing resection were assessed.
  • RESULTS: One hundred seventy-nine patients were studied (91 with colorectal cancer, 88 with adenomas).
  • Preoperative colorectal cancer platelet-derived growth factor-BB levels were higher (1,771.1 pg/ml; confidence intervals, 1,429-2,065) than in the benign neoplasm group (1083 pg/ml; confidence intervals, 933-1,192, P < 0.001).
  • In patients with colorectal cancer, a direct relationship was noted between platelet-derived growth factor-BB levels and disease severity.
  • CONCLUSION: Platelet-derived growth factor-BB levels were greater in patients with colorectal cancer (vs. patients with adenoma) and rose with increasing disease severity.
  • [MeSH-major] Adenoma / blood. Colorectal Neoplasms / blood. Platelet-Derived Growth Factor / metabolism
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Chi-Square Distribution. Enzyme-Linked Immunosorbent Assay. Female. Humans. Logistic Models. Male. Proto-Oncogene Proteins c-sis. Statistics, Nonparametric

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19581863.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Platelet-Derived Growth Factor; 0 / Proto-Oncogene Proteins c-sis; 0 / platelet-derived growth factor BB
  •  go-up   go-down


32. Wang W, Feng B, Li X, Yin P, Gao P, Zhao X, Lu X, Zheng M, Xu G: Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry. Mol Biosyst; 2010 Oct;6(10):1947-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Urinary metabolic profiling of colorectal carcinoma based on online affinity solid phase extraction-high performance liquid chromatography and ultra performance liquid chromatography-mass spectrometry.
  • Colorectal carcinoma (CRC) is the third most commonly encountered cancer and fourth cause of cancer-associated death worldwide.
  • In this study both ultra-performance liquid chromatography-mass spectrometry (UPLC-MS) and online affinity solid phase extraction-high performance liquid chromatography (SPE-HPLC) were used to analyze the urinary metabolites from 34 healthy volunteers, 34 benign colorectal tumor and 50 colorectal carcinoma patients to produce comprehensive metabolic profiling data.
  • [MeSH-major] Chromatography, High Pressure Liquid / methods. Colorectal Neoplasms / urine. Mass Spectrometry / methods

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20617254.001).
  • [ISSN] 1742-2051
  • [Journal-full-title] Molecular bioSystems
  • [ISO-abbreviation] Mol Biosyst
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


33. Piccolo SR, Frey LJ: Somatic mutation signatures of cancer. AMIA Annu Symp Proc; 2008 Nov 06;:202-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The advancement of cancer diagnosis, prognosis, and treatment would be hastened via a robust method to identify patterns that indicate a tumor's state.
  • Prior research has established that sporadic, colorectal-cancer pathogenesis involves a series of genetic mutations that allow benign polyps to develop and eventually progress to malignant tumors in distinguishable patterns.
  • Our results for colorectal cancer are consistent with what extant biological models as described in the literature.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Pharmacogenomics. 2007 Dec;8(12):1629-33 [18085994.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Br J Cancer. 2006 Jan 30;94(2):318-22 [16421597.001]
  • [Cites] Nucleic Acids Res. 2006 Jan 1;34(Database issue):D354-7 [16381885.001]
  • [Cites] Mol Cell Biol. 1992 Mar;12(3):1387-95 [1347643.001]
  • [Cites] N Engl J Med. 2008 Jan 31;358(5):502-11 [18234754.001]
  • [Cites] Nat Rev Cancer. 2004 Oct;4(10):769-80 [15510158.001]
  • [Cites] Nat Rev Cancer. 2004 Mar;4(3):197-205 [14993901.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 22;104(21):8685-90 [17502601.001]
  • [Cites] Bioinformatics. 2007 Oct 1;23(19):2507-17 [17720704.001]
  • (PMID = 18999255.001).
  • [ISSN] 1942-597X
  • [Journal-full-title] AMIA ... Annual Symposium proceedings. AMIA Symposium
  • [ISO-abbreviation] AMIA Annu Symp Proc
  • [Language] ENG
  • [Grant] United States / NLM NIH HHS / LM / T15 LM007124; United States / NLM NIH HHS / LM / 1T15-LM007124
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Genetic Markers; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2655983
  •  go-up   go-down


34. Hong R, Lim SC: Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report. World J Gastroenterol; 2009 Jul 14;15(26):3315-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Granular cell tumor of the cecum with extensive hyalinization and calcification: a case report.
  • A granular cell tumor (GCT) is a benign neoplasm of unclear histogenesis that is generally believed to be of nerve sheath origin.
  • In addition to the tumor, endoscopic examination revealed the presence of a 5-mm-polyp in the descending colon and multiple tiny polyps in the sigmoid colon and rectum.
  • Histological examination demonstrated a cecal tumor 1.5 cm x 1.0 cm x 0.7 cm with a hard consistency; in cut sections, mixed cells with yellowish and whitish portions were seen.
  • The tumor was located between the mucosa and subserosa, and was composed of plump histiocyte-like tumor cells with abundant granular eosinophilic cytoplasm, which were immunoreactive for S-100 protein, vimentin, neuron-specific enolase, inhibin-alpha and calretinin.
  • The tumor showed extensive hyalinization and focal dystrophic calcification.
  • Extensive hyalinization and calcification showing involution of tumor cells suggest benign clinical behavior of GCT.
  • [MeSH-major] Calcinosis / pathology. Cecum / pathology. Granular Cell Tumor / pathology. Hyalin / metabolism
  • [MeSH-minor] Biomarkers, Tumor. Calbindin 2. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / pathology. Humans. Male. Middle Aged. Phosphopyruvate Hydratase. S100 Calcium Binding Protein G. S100 Proteins. Vimentin

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ugeskr Laeger. 2006 May 22;168(21):2080-1 [16768929.001]
  • [Cites] J Oral Pathol Med. 1997 Apr;26(4):164-9 [9176790.001]
  • [Cites] J Craniofac Surg. 2008 Nov;19(6):1691-4 [19098584.001]
  • [Cites] J Oral Pathol Med. 2009 Jan;38(1):150-9 [19192059.001]
  • [Cites] J Gastroenterol. 2000;35(8):631-4 [10955603.001]
  • [Cites] Am J Surg Pathol. 2001 Sep;25(9):1200-3 [11688581.001]
  • [Cites] J Gastroenterol. 2003;38(4):385-9 [12743780.001]
  • [Cites] World J Gastroenterol. 2004 Aug 15;10(16):2452-4 [15285042.001]
  • [Cites] Mt Sinai J Med. 1979 Mar-Apr;46(2):195-8 [220528.001]
  • [Cites] J Surg Oncol. 1980;13(4):301-16 [6246310.001]
  • [Cites] Oral Surg Oral Med Oral Pathol. 1988 Apr;65(4):427-35 [2834681.001]
  • [Cites] Am J Gastroenterol. 1989 Jun;84(6):656-9 [2543214.001]
  • [Cites] Am J Gastroenterol. 1993 Feb;88(2):311-5 [8424442.001]
  • [Cites] Am J Gastroenterol. 1993 Oct;88(10):1785-7 [8213726.001]
  • [Cites] Pathologica. 1995 Apr;87(2):175-8 [8532413.001]
  • [Cites] Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 1995 Dec;80(6):687-97 [8680977.001]
  • [Cites] Nihon Shokakibyo Gakkai Zasshi. 1997 Jan;94(1):27-32 [9028140.001]
  • [Cites] Turk J Gastroenterol. 2008 Mar;19(1):73-4 [18386247.001]
  • (PMID = 19598311.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 0 / S100 Proteins; 0 / Vimentin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  • [Other-IDs] NLM/ PMC2710791
  •  go-up   go-down


35. Endo K, Oriuchi N, Higuchi T, Iida Y, Hanaoka H, Miyakubo M, Ishikita T, Koyama K: PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients. Int J Clin Oncol; 2006 Aug;11(4):286-96

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET and PET/CT using 18F-FDG in the diagnosis and management of cancer patients.
  • FDG-PET provides information that is not obtainable with other imaging modalities, and is very effective in the diagnosis and management of patients with various types of cancers.
  • PET and/or PET/CT using FDG is clinically useful in the detection of cancer, the differentiation of malignant and benign lesions, the staging of cancer before therapy, and the assessment of cancer therapy, as well as for determining the recurrence after therapy of most cancers, including lung cancer, gastrointestinal cancer, breast cancer, and malignant lymphoma.
  • PET/CT has become the new standard approach to imaging in the diagnosis and management of many cancer patients.
  • [MeSH-major] Fluorodeoxyglucose F18. Neoplasms / diagnosis. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, Emission-Computed / methods
  • [MeSH-minor] Breast Neoplasms / diagnosis. Breast Neoplasms / radionuclide imaging. Carcinoma / diagnosis. Carcinoma / radionuclide imaging. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / radionuclide imaging. Humans. Lung Neoplasms / diagnosis. Lung Neoplasms / radionuclide imaging. Lymphoma / diagnosis. Lymphoma / radionuclide imaging. Neoplasm Staging / methods. Whole Body Imaging / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16937302.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 51
  •  go-up   go-down


36. Jiang W, Fujii H, Matsumoto T, Ohtsuji N, Tsurumaru M, Hino O: Birt-Hogg-Dubé (BHD) gene mutations in human gastric cancer with high frequency microsatellite instability. Cancer Lett; 2007 Apr 8;248(1):103-11
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birt-Hogg-Dubé (BHD) syndrome is a rare inherited genodermatosis characterized by benign hamartomatous skin lesions and an increased risk of pneumothorax and renal tumors.
  • This mutational hot spot is also reported to be a target of mutation in microsatellite instability (MSI) sporadic colorectal tumors.
  • [MeSH-major] Microsatellite Instability. Mutation. Proteins / genetics. Proto-Oncogene Proteins / genetics. Stomach Neoplasms / pathology. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Base Sequence. DNA Mutational Analysis. Exons / genetics. Female. Gene Frequency. Humans. Male. Middle Aged. Neoplasm Staging. Poly C / genetics. Protein-Serine-Threonine Kinases. Receptors, Transforming Growth Factor beta / genetics. bcl-2-Associated X Protein / genetics

  • Genetic Alliance. consumer health - Birt-Hogg-Dube Syndrome.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16870330.001).
  • [ISSN] 0304-3835
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / FLCN protein, human; 0 / Proteins; 0 / Proto-Oncogene Proteins; 0 / Receptors, Transforming Growth Factor beta; 0 / Tumor Suppressor Proteins; 0 / bcl-2-Associated X Protein; 30811-80-4 / Poly C; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.30 / transforming growth factor-beta type II receptor
  •  go-up   go-down


37. Ruschenburg I, Vollheim B, Stachura J, Cordon-Cardo C, Korabiowska M: Analysis of DNA mismatch repair gene expression and mutations in thyroid tumours. Anticancer Res; 2006 May-Jun;26(3A):2107-12
MedlinePlus Health Information. consumer health - Thyroid Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Alterations of DNA mismatch repair genes, primarily demonstrated in hereditary nonpolyposis colorectal carcinomas, were reported to be of relevance for the progression of several sporadic tumours.
  • The expressions of MLH1, MSH2 and PMS1 were generally higher in malignant tumours than in benign lesions (p < 0.01).
  • [MeSH-major] Base Pair Mismatch. DNA Repair / genetics. Mutation. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adaptor Proteins, Signal Transducing. Adenocarcinoma, Follicular / genetics. Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adenoma / genetics. Adenoma / metabolism. Adenoma / pathology. Adenosine Triphosphatases / biosynthesis. Adenosine Triphosphatases / genetics. Adolescent. Adult. Aged. Base Sequence. Carcinoma, Papillary / genetics. Carcinoma, Papillary / metabolism. Carcinoma, Papillary / pathology. Carrier Proteins / biosynthesis. Carrier Proteins / genetics. DNA Repair Enzymes / biosynthesis. DNA Repair Enzymes / genetics. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Female. Gene Expression. Humans. Hyperplasia. Male. Middle Aged. Molecular Sequence Data. MutS Homolog 2 Protein / biosynthesis. MutS Homolog 2 Protein / genetics. Neoplasm Invasiveness. Neoplasm Proteins / biosynthesis. Neoplasm Proteins / genetics. Nuclear Proteins / biosynthesis. Nuclear Proteins / genetics. Thyroid Gland / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16827152.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / Carrier Proteins; 0 / DNA-Binding Proteins; 0 / MLH1 protein, human; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / PMS1 protein, human; EC 3.6.1.- / Adenosine Triphosphatases; EC 3.6.1.- / PMS2 protein, human; EC 3.6.1.3 / MSH2 protein, human; EC 3.6.1.3 / MutS Homolog 2 Protein; EC 6.5.1.- / DNA Repair Enzymes
  •  go-up   go-down


38. Guillem JG, Chessin DB, Jeong SY, Kim W, Fogarty JM: Contemporary applications of transanal endoscopic microsurgery: technical innovations and limitations. Clin Colorectal Cancer; 2005 Nov;5(4):268-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Transanal endoscopic microsurgery (TEM) is a minimally invasive procedure used to transanally excise select benign and malignant tumors of the rectum.
  • PATIENTS AND METHODS: Thirty-two consecutive patients scheduled for TEM were identified from our prospectively maintained colorectal service database.
  • In addition, a PubMed literature search was performed with use of the key words "transanal endoscopic microsurgery," "TEM," "rectal tumor," and "rectal cancer."
  • RESULTS: Transanal endoscopic microsurgery was performed for rectal adenocarcinoma (n = 17; 53%), adenoma (n = 12; 38%), and carcinoid tumors (n = 3; 9%).
  • Median tumor location was 9 cm from the anal verge (range, 3-15 cm).
  • Reasons for inability to complete TEM included narrow rectal lumen or contour of bony pelvis prohibiting passage of the operating proctoscope into the upper rectum and inability to maintain the proctoscope in the rectal lumen with carbon dioxide insufflation because of the distal location of the tumor.
  • Innovations used in the excision of rectal tumors via TEM included the use of the harmonic scalpel, closure of the rectal defect with an extracorporeal slip knot, and a hybrid approach incorporating TEM and traditional transanal techniques.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoid Tumor / surgery. Colonoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Female. Humans. Male. Microsurgery. Middle Aged. Neoplasm Staging. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16356304.001).
  • [ISSN] 1533-0028
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


39. Sajid MS, Rimpel J, Iftikhar M, Baig MK: Use of health related quality of life tools in colorectal surgery. Acta Chir Belg; 2007 Nov-Dec;107(6):623-9
MedlinePlus Health Information. consumer health - Rectal Disorders.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of health related quality of life tools in colorectal surgery.
  • OBJECTIVE: The objective of this article is to discuss the various tools used in colorectal surgery for the measurement of health related quality of life (HR-QOL) and highlight various outcome variables that affect the HR-QOL.
  • METHODS: Review of HR-QOL articles published on various colorectal procedures in last 25 years.
  • These HR-QOL tools are very helpful for the evaluation of subjective outcome of common colorectal procedures.
  • Gastrointestinal Quality of Life Index (GIQLI) for benign anorectal conditions, European Organization for the Research and Treatment of Cancer (EORTC QLQ-C30), EORTC QLQ-CR38 and Functional Assessment of Cancer Therapy-Colorectal (FACT-C) for colorectal cancer and Inflammatory Bowel Disease Questionnaire (IBDQ) for all types of inflammatory bowel disease are being used frequently to assess the quality of life after surgery.
  • CONCLUSION: The use of validated and reliable health instruments in colorectal surgery is directed at measuring the impact in a reproducible and valid fashion.
  • Curative or palliative procedures should be offered to the patients of colorectal disorders after the assessment by HR-QOL tools.
  • [MeSH-minor] Colonic Neoplasms / surgery. Colonic Pouches. Digestive System Surgical Procedures. Humans. Inflammatory Bowel Diseases / surgery. Laparoscopy. Neoplasm Recurrence, Local / surgery. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18274174.001).
  • [ISSN] 0001-5458
  • [Journal-full-title] Acta chirurgica Belgica
  • [ISO-abbreviation] Acta Chir. Belg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Belgium
  • [Number-of-references] 77
  •  go-up   go-down


40. Croce MV, Isla-Larrain M, Remes-Lenicov F, Colussi AG, Lacunza E, Kim KC, Gendler SJ, Segal-Eiras A: MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue. Histol Histopathol; 2006 08;21(8):849-55
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MUC1 cytoplasmic tail detection using CT33 polyclonal and CT2 monoclonal antibodies in breast and colorectal tissue.
  • MATERIALS AND METHODS: We studied 163 breast and 89 colorectal cancer specimens, 10 breast and 14 colorectal benign conditions, and 12 breast and 20 colorectal normal samples.
  • From each tumor sample, subcellular fractions were obtained and analyzed by SDS-PAGE and WB.
  • Seven out of ten (70%) benign breast specimens were positive with CT33 while all samples stained with CT2; in normal breast sample tissues, all were positive with both Abs.
  • In colorectal cancer samples, both antibodies stained 47/89 (53%) samples; CT2 reacted in 13/14 (93%) of benign samples while CT33 showed a positive reaction in 9/14 (64%) of benign specimens.
  • By WB, in breast and colorectal cancer samples, similar results were obtained with both antibodies: a main band at about 30kDa which represents the smaller subunit.
  • CONCLUSION: CT33 polyclonal antibody has demonstrated its efficacy to detect MUC1 in breast and colorectal cancer tissues with similar reactivity to CT2.
  • [MeSH-major] Antibodies, Monoclonal / metabolism. Breast Neoplasms / metabolism. Colorectal Neoplasms / metabolism. Mucin-1 / metabolism. Organic Cation Transport Proteins / metabolism
  • [MeSH-minor] Antibodies, Neoplasm / immunology. Antibodies, Neoplasm / metabolism. Biomarkers, Tumor. Breast / anatomy & histology. Breast / metabolism. Breast / pathology. Cell Fractionation. Colon / anatomy & histology. Colon / metabolism. Colon / pathology. Humans. Immunoenzyme Techniques. Rectum / anatomy & histology. Rectum / metabolism. Rectum / pathology

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16691537.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; 0 / Biomarkers, Tumor; 0 / MUC-1 monoclonal antibody; 0 / Mucin-1; 0 / Organic Cation Transport Proteins; 0 / SLC22A16 protein, human
  •  go-up   go-down


41. Davies M, Arumugam PJ, Shah VI, Watkins A, Roger Morgan A, Carr ND, Beynon J: The clinical significance of lymph node micrometastasis in stage I and stage II colorectal cancer. Clin Transl Oncol; 2008 Mar;10(3):175-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical significance of lymph node micrometastasis in stage I and stage II colorectal cancer.
  • The aim of the study was to determine the prevalence and prognostic significance of immunohistochemically detected micrometastasis (IHM) in patients with localised colorectal cancer (CRC) (Dukes' A and B).
  • There was no correlation of IHM with age, gender, site, size and grade of tumour, depth of tumour invasion or perineural and vascular invasion.
  • DISCUSSION: We have shown that isolated CK-positive epithelioid cells are commonly found in morphologically benign pericolic lymph nodes of patients with localised (Dukes' A or B) CRC.
  • [MeSH-major] Adenocarcinoma / secondary. Colorectal Neoplasms / pathology. Lymph Nodes / pathology. Neoplasm Recurrence, Local / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Humans. Keratins / metabolism. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18321821.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 68238-35-7 / Keratins
  •  go-up   go-down


42. Gottwald L, Korczyński J, Góra E, Bieńkiewicz A: [Adnexal tumors after surgical treatment of colorectal cancer]. Ginekol Pol; 2008 Apr;79(4):259-63
MedlinePlus Health Information. consumer health - Ovarian Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adnexal tumors after surgical treatment of colorectal cancer].
  • OBJECTIVE: The risk of metastatic ovarian tumor is significantly higher in case of women with a history of colorectal cancer.
  • DESIGN: The purpose of the study was to evaluate the clinical presentation and histopathology of adnexal tumors in case of female patients with a history of colorectal adenocarcinoma.
  • MATERIAL AND METHODS: A retrospective study on 13 women (each with a history of colorectal carcinoma, operated due to adnexal tumor between 2004 and 2007), has been conducted.
  • Subject characteristics, ultrasound, CT, serum tumor markers levels, histopathology and findings at surgery were analyzed.
  • RESULTS: Time distance between colorectal cancer surgery and ovarian tumor operation - measured in months -was shorter in cases of malignant neoplasms (10.13 +/- 3.98) than in benign tumors (26.2 +/- 19.37).
  • Ultrasound examination showed solid-cystic adnexal tumors in 8 malignant cases, and ovarian cysts in 5 benign conditions.
  • Unilateral adnexectomy only took place in one case of benign tumor and in one case of disseminated neoplasmatic disease.
  • CONCLUSIONS: When evaluating a patient with an adnexal tumor, a history of malignancy strongly suggests a metastatic nature.
  • The use of ultrasound associated with plasma levels of Ca 125, Ca 19-9 and CEA, represents a useful method of preoperative assessment of ovarian tumors.
  • [MeSH-major] Colorectal Neoplasms / pathology. Colorectal Neoplasms / surgery. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / secondary
  • [MeSH-minor] Adult. CA-125 Antigen / blood. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Female. Humans. Middle Aged. Neoplasm Staging. Poland. Retrospective Studies. Risk Assessment. Ultrasonography, Doppler, Color / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18592863.001).
  • [ISSN] 0017-0011
  • [Journal-full-title] Ginekologia polska
  • [ISO-abbreviation] Ginekol. Pol.
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / CA-125 Antigen; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


43. Bretthauer M, Hoff G: [Prevention and early diagnosis of colorectal cancer]. Tidsskr Nor Laegeforen; 2007 Oct 18;127(20):2688-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prevention and early diagnosis of colorectal cancer].
  • BACKGROUND: Colorectal cancer (CRC) is one of the most common cancers in Norway.
  • CRC develops from benign adenomas in the colon over a long time.
  • MATERIAL AND METHODS: Medline was systematically searched using the MeSH terms "Colorectal neoplasm AND prevention and control", with a limitation on randomised trials in humans.
  • [MeSH-major] Colorectal Neoplasms
  • [MeSH-minor] Colon / radiography. Colonoscopy. Early Diagnosis. Evidence-Based Medicine. Humans. Mass Screening. Occult Blood. Prognosis. Randomized Controlled Trials as Topic. Sigmoidoscopy

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17952153.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Norway
  • [Number-of-references] 35
  •  go-up   go-down


44. McIntosh J, Sylvester PA, Virjee J, Callaway M, Thomas MG: Pulmonary staging in colorectal cancer--is computerised tomography the answer? Ann R Coll Surg Engl; 2005 Sep;87(5):331-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary staging in colorectal cancer--is computerised tomography the answer?
  • INTRODUCTION: Pulmonary staging in colorectal cancer (CRC) has traditionally been carried out by means of plain chest radiograph (CXR), although computerised tomography (CT) imaging of the chest is increasingly being performed for this purpose.
  • Patients with a CRC went on to have a staging intravenous, contrast-enhanced CT of the chest, abdomen and pelvis prior to an out-patient appointment with a colorectal surgeon.
  • In addition, one of the patients underwent multiple, non-diagnostic thoracic investigations prior to a diagnosis of sarcoidosis being made and then proceeding to surgery.
  • An independent consultant radiologist reviewed seven out of the nine CXRs of patients with an abnormality on thoracic CT without knowledge of the clinical diagnosis, and reported three of the CXRs to be normal.
  • However, CT is likely to identify more benign radiological abnormalities than CXR alone, and investigations should not occur to the detriment of treating the primary tumour.
  • [MeSH-major] Colorectal Neoplasms. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Neoplasm Staging / standards. Prospective Studies. Sensitivity and Specificity


45. Grossmann I, Avenarius JK, Mastboom WJ, Klaase JM: Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure. Ann Surg Oncol; 2010 Aug;17(8):2045-50
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Preoperative staging with chest CT in patients with colorectal carcinoma: not as a routine procedure.
  • BACKGROUND: Preoperative staging of patients with colorectal carcinoma (CRC) has the potential benefit of altering treatment options when metastases are present.
  • MATERIALS AND METHODS: All patients who undergo colorectal surgery in our hospital are prospectively registered, including patient, treatment, and histopathological characteristics; outcome; and follow-up.
  • These were diagnosed during follow-up as true metastases (n = 8), bronchus carcinoma (n = 2), benign lesions (n = 25), and remaining unknown (n = 15).
  • In none of the patients the treatment plan for the primary tumor was changed based on the staging chest CT.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lung Neoplasms / radiography. Lung Neoplasms / secondary. Neoplasm Staging / methods. Preoperative Care. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Comput Assist Tomogr. 2007 Jul-Aug;31(4):569-71 [17882033.001]
  • [Cites] Onkologie. 2007 Mar;30(3):141-5 [17341902.001]
  • [Cites] Ann R Coll Surg Engl. 2007 Nov;89(8):744-8 [17999813.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):1026-32 [19184237.001]
  • [Cites] Colorectal Dis. 2009 Jul;11(6):592-600 [18624816.001]
  • [Cites] Colorectal Dis. 2007 Nov;9(9):816-8 [17931171.001]
  • [Cites] Radiology. 2001 Jan;218(1):55-60 [11152779.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 May;21(5):906-12 [12062285.001]
  • [Cites] Ann Surg Oncol. 1998 Jan-Feb;5(1):9-15 [9524701.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):229-35 [10421258.001]
  • [Cites] Annu Rev Med. 2005;56:139-56 [15660506.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2005 Jan;53(1):22-8 [15724498.001]
  • [Cites] Ann R Coll Surg Engl. 2005 Sep;87(5):331-3 [16176690.001]
  • [Cites] Radiat Med. 2005 Sep;23(6):418-26 [16389984.001]
  • [Cites] Surgery. 2007 Jan;141(1):67-75 [17188169.001]
  • [CommentIn] Ann Surg Oncol. 2011 Dec;18 Suppl 3:S224-5; author reply S226-7 [20839065.001]
  • (PMID = 20151212.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2899025
  •  go-up   go-down


46. Huang Z, Li L, Wang J: Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions. Dig Dis Sci; 2007 Sep;52(9):2287-91
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of SFRP2 as a potential marker for stool-based detection of colorectal cancer and precancerous lesions.
  • DNA methylation is a key mechanism of colorectal carcinogenesis.
  • Analysis of aberrantly methylation in stool DNA might provide a novel strategy for noninvasive detection of colorectal cancer (CRC).
  • To explore the feasibility of this approach, we have assessed the methylation status of secreted frizzled-related protein gene 2 (SFRP2) in stool samples from patients with CRC with respect to a series of healthy individuals and patients with benign colorectal diseases, using methylation-specific polymerase chain reaction.
  • Methylation testing of fecal DNA may be a simple, promising, and noninvasive screening tool for colorectal neoplasia.
  • [MeSH-major] Biomarkers, Tumor / genetics. Colorectal Neoplasms. DNA Methylation. DNA, Neoplasm / analysis. Feces / chemistry. Membrane Proteins / genetics. Precancerous Conditions
  • [MeSH-minor] Apoptosis. Biopsy. Colonoscopy. Diagnosis, Differential. Disease Progression. Humans. Polymerase Chain Reaction. Prognosis. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17410438.001).
  • [ISSN] 0163-2116
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 0 / Membrane Proteins; 0 / SFRP2 protein, human
  •  go-up   go-down


47. Strum WB: Impact of a family history of colorectal cancer on age at diagnosis, anatomic location, and clinical characteristics of colorectal cancer. Int J Gastrointest Cancer; 2005;35(2):121-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of a family history of colorectal cancer on age at diagnosis, anatomic location, and clinical characteristics of colorectal cancer.
  • BACKGROUND: Among the risk factors for colorectal cancer (CRC) is a family history of colorectal cancer.
  • AIM OF THE STUDY: This study set out to determine specific clinical outcomes in patients with CRC with a family history of one first-degree relative with sporadic colorectal cancer compared to control patients with colorectal cancer but without the family history.
  • METHODS: We designed a case-control study of colorectal cancer registry data between 1988 and 1999.
  • Patients with a family history of one first-degree relative with colorectal cancer were compared to those without the history with regard to four characteristics: age at cancer diagnosis, anatomic location of the cancer, presence of distal adenomas with proximal cancer, and stage of disease at diagnosis.
  • The anatomic location of the cancer, presence of distal benign neoplasia when the cancer was proximal, and disease stage at diagnosis were not different between the groups.
  • CONCLUSIONS: Men with a family history of sporadic colorectal cancer and proximal colon cancer were younger than men without the family history and proximal colon cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Neoplasm Staging

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15879626.001).
  • [ISSN] 1537-3649
  • [Journal-full-title] International journal of gastrointestinal cancer
  • [ISO-abbreviation] Int J Gastrointest Cancer
  • [Language] eng
  • [Grant] United States / NCRR NIH HHS / RR / RR00833
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


48. Lim GH, Koh DC, Cheong WK, Wong KS, Tsang CB: Natural history of small, "indeterminate" hepatic lesions in patients with colorectal cancer. Dis Colon Rectum; 2009 Aug;52(8):1487-91
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Natural history of small, "indeterminate" hepatic lesions in patients with colorectal cancer.
  • PURPOSE: The initial staging CT scan for patients with colorectal cancer may reveal small, "indeterminate" hepatic lesions.
  • The significance of these lesions is often unknown at the time of diagnosis.
  • This study was designed to determine the prevalence and significance of small (<1 cm on CT scan), indeterminate liver lesions detected preoperatively in patients with colorectal cancer and to determine whether further surveillance imaging of these patients is required.
  • All colorectal cancer patients with small, indeterminate liver lesions on their initial staging CT scan were included.
  • RESULTS: Four hundred nineteen patients with colorectal cancer had staging CT performed.
  • Forty-one (89.1%) of these were shown to be stable lesions that were likely benign.
  • CONCLUSION: Small, indeterminate liver lesions may occur in up to 16.7% of patients with colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prevalence. Prognosis. Retrospective Studies. Singapore / epidemiology. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19617765.001).
  • [ISSN] 1530-0358
  • [Journal-full-title] Diseases of the colon and rectum
  • [ISO-abbreviation] Dis. Colon Rectum
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Brosseuk D, Oosthuizen J, Pinchbeck M: Initial experience with a general population colorectal cancer screening clinic. Am J Surg; 2006 May;191(5):669-72
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial experience with a general population colorectal cancer screening clinic.
  • BACKGROUND: Recognition of adenoma to carcinoma progression has established colorectal cancer as a preventable malignancy.
  • Colorectal cancer is, therefore, an ideal malignancy for preventative screening given the presence of a benign precursor.
  • METHODS: A retrospective chart review of all patients referred to a new low-risk colorectal cancer endoscopic screening clinic from October 1, 2004 to September 30, 2005 was performed.
  • Those patients found to have adenomas or carcinomas were analyzed further regarding location of neoplasm and pathologic findings.
  • RESULTS: A total of 379 low-risk patients attended the colorectal cancer screening clinics.
  • Of the 67 patients with neoplasms, 50 were left of the splenic flexure, 11 were right of the splenic flexure, and 5 patients had lesions both proximal and distal to the flexure.
  • Thirty-two of the 67 patients had complete colonoscopy at the initial procedure and, thus far, 21 patients have had completion colonoscopies, of which 9 patients had further neoplasms identified beyond the splenic flexure.
  • All 3 patients with carcinoma had early tumors resected with curative intent, with negative margins and negative nodes.
  • CONCLUSIONS: Our initial experience with a low-risk general population colorectal cancer endoscopic screening clinic yielded 18% of patients with neoplasms, and 1% had curable cancers resected.
  • [MeSH-major] Cancer Care Facilities. Colonoscopy. Colorectal Neoplasms / diagnosis. Mass Screening / methods
  • [MeSH-minor] Aged. Aged, 80 and over. British Columbia / epidemiology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Retrospective Studies. Risk Factors. Video Recording

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16647357.001).
  • [ISSN] 0002-9610
  • [Journal-full-title] American journal of surgery
  • [ISO-abbreviation] Am. J. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


50. Votrubova J, Belohlavek O, Jaruskova M, Oliverius M, Lohynska R, Trskova K, Sedlackova E, Lipska L, Stahalova V: The role of FDG-PET/CT in the detection of recurrent colorectal cancer. Eur J Nucl Med Mol Imaging; 2006 Jul;33(7):779-84
MedlinePlus Health Information. consumer health - CT Scans.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of FDG-PET/CT in the detection of recurrent colorectal cancer.
  • PURPOSE: The conventional diagnostic techniques used to assess recurrence of colorectal cancer (CRCR) often yield unspecific findings.
  • Integrated FDG-PET/CT seems to offer promise for the differential diagnosis of benign and malignant lesions.
  • The sensitivity, specificity and accuracy of PET and PET/CT were calculated for (a) intra-abdominal extrahepatic recurrences, (b) extra-abdominal and/or hepatic recurrences and (c) all recurrences, and tumour marker levels were analysed.
  • Two of these cases were due to increased accumulation in inflammatory foci in the bowel wall, while one was due to haemorrhaging into the adrenal gland.
  • CONCLUSION: FDG-PET/CT appears to be a very promising method for distinguishing a viable tumour from fibrous changes, thereby avoiding unnecessary laparotomy.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / surgery. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / prevention & control. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16565845.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


51. Kim J, Roh M, Abdulkadir SA: Pim1 promotes human prostate cancer cell tumorigenicity and c-MYC transcriptional activity. BMC Cancer; 2010 Jun 01;10:248
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: The serine/threonine kinase PIM1 has been implicated as an oncogene in various human cancers including lymphomas, gastric, colorectal and prostate carcinomas.
  • However, there has been limited analysis of the tumorigenic potential of Pim1 overexpression in benign and malignant human prostate cancer cells in vivo.
  • METHODS: We overexpressed Pim1 in three human prostate cell lines representing different disease stages including benign (RWPE1), androgen-dependent cancer (LNCaP) and androgen-independent cancer (DU145).
  • RESULTS: Overexpression of Pim1 alone was not sufficient to convert the benign RWPE1 cell to malignancy although it enhanced their proliferation rates when grown as xenografts in vivo.
  • Reporter assays revealed increased c-MYC transcriptional activity in Pim1-expressing cells and mRNA expression profiling demonstrated that a large fraction of c-MYC target genes were also regulated by Pim1 expression.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2000 May 1;60(9):2335-41 [10811103.001]
  • [Cites] Exp Hematol. 2006 Nov;34(11):1480-9 [17046567.001]
  • [Cites] Nature. 2001 Jul 19;412(6844):341-6 [11460166.001]
  • [Cites] Nature. 2001 Aug 23;412(6849):822-6 [11518967.001]
  • [Cites] Chromosoma. 2002 Jul;111(2):80-95 [12111331.001]
  • [Cites] Biochim Biophys Acta. 2002 Dec 16;1593(1):45-55 [12431783.001]
  • [Cites] Blood. 2003 Sep 1;102(5):1833-41 [12714522.001]
  • [Cites] Lab Invest. 2003 Sep;83(9):1301-9 [13679438.001]
  • [Cites] Oncogene. 2003 Sep 18;22(40):6151-9 [13679853.001]
  • [Cites] Cancer Cell. 2003 Sep;4(3):223-38 [14522256.001]
  • [Cites] Cancer Res. 2003 Dec 1;63(23):8079-84 [14678956.001]
  • [Cites] Blood. 2004 Mar 1;103(5):1869-75 [14592832.001]
  • [Cites] Oncogene. 2004 Mar 11;23(10):1838-44 [14981536.001]
  • [Cites] Prostate. 2004 Sep 1;60(4):367-71 [15264249.001]
  • [Cites] FEBS Lett. 2004 Jul 30;571(1-3):43-9 [15280015.001]
  • [Cites] Cancer Res. 1977 Nov;37(11):4049-58 [908039.001]
  • [Cites] Int J Cancer. 1978 Mar 15;21(3):274-81 [631930.001]
  • [Cites] Prog Clin Biol Res. 1980;37:115-32 [7384082.001]
  • [Cites] Prog Clin Biol Res. 1980;37:67-84 [7384095.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1809-18 [6831420.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;105(1):20-3 [6833336.001]
  • [Cites] Cancer Res. 1983 Nov;43(11):5228-34 [6616459.001]
  • [Cites] Cell. 1989 Feb 24;56(4):673-82 [2537153.001]
  • [Cites] Nature. 1989 Jul 6;340(6228):61-3 [2786994.001]
  • [Cites] Oncogene. 1991 Nov;6(11):1941-8 [1658705.001]
  • [Cites] Carcinogenesis. 1997 Jun;18(6):1215-23 [9214605.001]
  • [Cites] J Biol Chem. 1999 Jun 25;274(26):18659-66 [10373478.001]
  • [Cites] Anticancer Drugs. 2007 Feb;18(2):161-70 [17159602.001]
  • [Cites] Nat Cell Biol. 2007 Aug;9(8):932-44 [17643117.001]
  • [Cites] Mol Cancer Ther. 2007 Sep;6(9):2399-408 [17876039.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):5076-85 [18593906.001]
  • [Cites] PLoS One. 2008;3(7):e2572 [18596907.001]
  • [Cites] Oncogene. 2008 Aug 14;27(35):4809-19 [18438430.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2144-51 [18715779.001]
  • [Cites] Cancer Chemother Pharmacol. 2009 Mar;63(4):615-25 [18509642.001]
  • [Cites] PLoS Genet. 2009 Jul;5(7):e1000542 [19578399.001]
  • [Cites] Oncogene. 2009 Dec 3;28(48):4261-71 [19749799.001]
  • [Cites] Oncogene. 2010 Apr 29;29(17):2477-87 [20140016.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):48319-28 [15319445.001]
  • [Cites] J Biol Chem. 2005 Feb 18;280(7):6130-7 [15525646.001]
  • [Cites] J Pathol. 2005 May;206(1):87-91 [15809970.001]
  • [Cites] Mol Cancer Res. 2005 Aug;3(8):443-51 [16123140.001]
  • [Cites] J Biol Chem. 2005 Dec 9;280(49):40568-77 [16221667.001]
  • [Cites] Leukemia. 2006 Mar;20(3):539-42 [16437153.001]
  • [Cites] J Clin Pathol. 2006 Mar;59(3):285-8 [16505280.001]
  • [Cites] Nat Med. 2001 Jan;7(1):101-7 [11135623.001]
  • (PMID = 20515470.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01CA123484
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 5-(4-ethylbenzylidene)-2-thioxothiazolidin-4-one; 0 / AR protein, human; 0 / MYC protein, human; 0 / Proto-Oncogene Proteins c-myc; 0 / RNA, Messenger; 0 / Receptors, Androgen; 0 / Thiazoles; EC 2.7.11.1 / Proto-Oncogene Proteins c-pim-1
  • [Other-IDs] NLM/ PMC2886047
  •  go-up   go-down


52. Hauenschild L, Bader FG, Laubert T, Czymek R, Hildebrand P, Roblick UJ, Bruch HP, Mirow L: Laparoscopic colorectal resection for benign polyps not suitable for endoscopic polypectomy. Int J Colorectal Dis; 2009 Jul;24(7):755-9
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laparoscopic colorectal resection for benign polyps not suitable for endoscopic polypectomy.
  • BACKGROUND AND AIMS: Endoscopic polypectomy still remains the cornerstone of therapy for colorectal polyps and adenomas.
  • However, if colorectal polyps are too large or not accessible for endoscopic ablation or cannot be removed without an increased risk for perforation, operative procedures are required.
  • In patients which could not be treated by endoscopic polypectomy due to size, location, and/or risk of complications, a laparoscopic colorectal resection was performed.
  • All data were prospectively assessed in our "colorectal resection" database.
  • RESULTS: The database analysis revealed 58 patients with endoscopically not resectable colorectal polyps who underwent a laparoscopic colorectal resection (intend to treat).
  • The histopathological work-up revealed benign disease in all cases.
  • CONCLUSION: Laparoscopic resection of colorectal polyps is a safe and minimally invasive technique for the management of benign colorectal tumors.
  • [MeSH-major] Colonic Polyps / pathology. Colonic Polyps / surgery. Colorectal Surgery. Endoscopy. Laparoscopy

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19283390.001).
  • [ISSN] 1432-1262
  • [Journal-full-title] International journal of colorectal disease
  • [ISO-abbreviation] Int J Colorectal Dis
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


53. Gopalan A, Sharp DS, Fine SW, Tickoo SK, Herr HW, Reuter VE, Olgac S: Urachal carcinoma: a clinicopathologic analysis of 24 cases with outcome correlation. Am J Surg Pathol; 2009 May;33(5):659-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DESIGN: We reviewed histologic material and clinical data from 24 cases selected from a database of 67 dome-based tumors diagnosed and treated at our institution from 1984 to 2005.
  • RESULT: The mean age at diagnosis was 52 years (range: 26 to 68 y).
  • In all instances but 1, cystitis cystica/glandularis was focal and predominantly in the bladder overlying the urachal neoplasm.
  • Urachal remnants were identified in 15 cases: the urachal epithelium was benign urothelial-type in 6 cases and showed adenomatous changes in 9.
  • In all 3, urachal remnants were identified and showed transition from benign to adenomatous epithelium.
  • On immunohistochemistry, these tumors were positive for CK20 and variably positive for CK7 and 34BE12.
  • Surface urothelial involvement by carcinoma and presence of cystitis cystica/glandularis do not necessarily exclude the diagnosis of urachal carcinoma.
  • Immunostains do not unequivocally discriminate a urachal from a colorectal carcinoma, but diffuse positivity for 34BE12 would support, and diffuse nuclear immunoreactivity for beta-catenin would militate against, a diagnosis of urachal carcinoma.
  • Local recurrence may be owing to seeding within the distal urothelial tract, particularly in tumors with a configuration that is polypoid and which open into the bladder cavity.
  • [MeSH-major] Carcinoma / pathology. Urachus / pathology. Urinary Bladder Neoplasms / pathology. Urothelium / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adult. Aged. Carcinoma, Signet Ring Cell / pathology. Chemotherapy, Adjuvant. Cystectomy. Cystitis / pathology. Databases as Topic. Female. Homeodomain Proteins / analysis. Humans. Immunohistochemistry. Keratin-20 / analysis. Keratin-7 / analysis. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Recurrence, Local. Neoplasm Staging. Radiotherapy, Adjuvant. Treatment Outcome. Umbilicus / surgery. beta Catenin / analysis

  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1380-7 [11684954.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2434-40 [17932892.001]
  • [Cites] J Urol. 2003 Apr;169(4):1295-8 [12629346.001]
  • [Cites] Arch Pathol Lab Med. 2004 Apr;128(4):456-9 [15043458.001]
  • [Cites] J Urol. 1982 Jan;127(1):40-2 [7057501.001]
  • [Cites] Urology. 1983 Apr;21(4):360-6 [6836822.001]
  • [Cites] J Urol. 1984 Jan;131(1):1-8 [6361280.001]
  • [Cites] Urol Res. 1983;11(5):235-8 [6659216.001]
  • [Cites] Urology. 1985 Sep;26(3):218-21 [4035835.001]
  • [Cites] J Urol. 1986 Jun;135(6):1240-4 [3712579.001]
  • [Cites] Cancer. 1991 Apr 15;67(8):2165-72 [1706216.001]
  • [Cites] J Urol. 1994 Feb;151(2):365-6 [8283526.001]
  • [Cites] Hum Pathol. 1996 Mar;27(3):240-7 [8600037.001]
  • [Cites] Cancer. 1955 Jul-Aug;8(4):741-58 [13240656.001]
  • [Cites] Mod Pathol. 2005 Sep;18(9):1217-22 [15803184.001]
  • [Cites] Semin Diagn Pathol. 2005 Feb;22(1):69-87 [16512600.001]
  • [Cites] J Urol. 2006 Jun;175(6):2042-7; discussion 2047 [16697798.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):712-20 [16826585.001]
  • [Cites] Cancer. 2006 Aug 15;107(4):721-8 [16826584.001]
  • [Cites] J Urol. 2007 Jul;178(1):74-8; discussion 78 [17499279.001]
  • [Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]
  • (PMID = 19252435.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082088
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDX2 protein, human; 0 / CTNNB1 protein, human; 0 / Homeodomain Proteins; 0 / KRT20 protein, human; 0 / KRT7 protein, human; 0 / Keratin-20; 0 / Keratin-7; 0 / beta Catenin
  • [Other-IDs] NLM/ NIHMS627175; NLM/ PMC4225778
  •  go-up   go-down


54. Céspedes MV, Sancho FJ, Guerrero S, Parreño M, Casanova I, Pavón MA, Marcuello E, Trias M, Cascante M, Capellà G, Mangues R: K-ras Asp12 mutant neither interacts with Raf, nor signals through Erk and is less tumorigenic than K-ras Val12. Carcinogenesis; 2006 Nov;27(11):2190-200
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Different mutant amino acids in the Ras proteins lead to distinct transforming capacities and different aggressiveness in human tumors.
  • K-Ras Asp12 (K12D) is more prevalent in benign than in malignant human colorectal tumors, whereas K-Ras Val12 (K12V) associates with more advanced and metastatic carcinomas, higher recurrence and decreased survival.
  • We studied tumor histology and growth, apoptotic and mitotic rates, activation of signal transduction pathways downstream of Ras and regulation of the cell cycle and apoptotic proteins in tumors derived from the implanted transformants.
  • We found that the K12V oncogene induces a more aggressive tumorigenic phenotype than the K12D oncogene, whereas K12C does not induce tumors in this model.
  • Thus, K12V mutant tumors proliferate about seven times faster, and have higher cellularity and mitotic rates than the K12D mutant tumors.
  • A molecular analysis of the induced tumors shows that the K12V mutant protein interacts with Raf-1 and transduces signals mainly through the Erk pathway.
  • Unexpectedly, in tumors induced by the K12D oncogene, the K-Ras mutant protein does not interact with Raf-1 nor activates the Erk canonical pathway.
  • Finally, the higher growth rate of the K12V tumors associates with enhanced Rb phosphorylation, and PCNA and cyclin B upregulation, consistent with faster G1/S and G2/M transitions, without alteration of apoptotic regulation.
  • [MeSH-minor] Animals. Apoptosis. Male. Mice. Mice, Nude. NIH 3T3 Cells. Neoplasm Metastasis. Protein Binding. Signal Transduction


55. Yoon HE, Fukuhara K, Michiura T, Takada M, Imakita M, Nonaka K, Iwase K: Pulmonary nodules 10 mm or less in diameter with ground-glass opacity component detected by high-resolution computed tomography have a high possibility of malignancy. Jpn J Thorac Cardiovasc Surg; 2005 Jan;53(1):22-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: For the histological diagnosis of small lung cancers of 10 mm or less in diameter (< or =10), resection by video-assisted thoracic surgery (VATS) with computed tomography (CT)-guided marking is feasible.
  • RESULTS: The histology of all 94 nodules showed 52 primary lung cancers, 6 metastatic tumors, 5 benign tumors, 8 intrapulmonary lymph nodes, and 23 inflammatory nodules.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Small Cell / radiography. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Solitary Pulmonary Nodule / pathology. Solitary Pulmonary Nodule / radiography. Tomography, X-Ray Computed
  • [MeSH-minor] Colorectal Neoplasms / pathology. Colorectal Neoplasms / radiography. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Patient Selection. Predictive Value of Tests. Retrospective Studies. Thoracic Surgery, Video-Assisted

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15724498.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. Oh SJ, Lee SJ, Lee HY, Paik YH, Lee DK, Lee KS, Chung JB, Yu JS, Yoon DS: [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas]. Korean J Gastroenterol; 2009 Sep;54(3):162-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Extrapancreatic tumors in intraductal papillary mucinous neoplasm of the pancreas].
  • BACKGROUND/AIMS: Intraductal papillary mucinous neoplasm (IPMN) of the pancreas has a favorable prognosis, but seems to be associated with a high incidence of extrapancreatic tumors.
  • The purpose of this study was to evaluate the incidence and clinicopathological features of extrapancreatic tumors associated with IPMN.
  • These patients were examined for the development of extrapancreatic tumors.
  • RESULTS: Of 37 patients with IPMN, 14 (38%) had 18 extrapancreatic tumors, and 10 (27%) had 13 extrapancreatic malignancies.
  • Five, six, and two extrapancreatic malignancies had been diagnosed before, during, and after the diagnosis of IPMN.
  • Gastric adenocarcinoma (3 patients, 23%) and colorectal carcinoma (3 patients, 23%) were the most common neoplasms.
  • Other extrapancreatic tumors included lung cancer (n=2), prostatic cancer (n=1), renal cell carcinoma (n=1), cholangiocellular carcinoma (n=1), urinary bladder cancer (n=1), and gallbladder cancer (n=1), respectively.
  • As benign tumor, there were two gallbladder adenoma, one gastric adenoma, one colonic adenoma and one benign ovarian cystic neoplasm, respectively.
  • CONCLUSIONS: IPMN is associated with high incidence of extrapancreatic tumors, particularly gastric and colorectal neoplasms.
  • Upper gastrointestinal endoscopy and colonoscopy should be done, and systemic surveillance for the possible occurrence of other tumors may allow early detection of extrapancreatic tumor in patients with IPMN.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Carcinoma, Pancreatic Ductal / diagnosis. Carcinoma, Papillary / diagnosis. Neoplasms, Multiple Primary / epidemiology. Neoplasms, Second Primary / epidemiology. Pancreatic Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Korean J Gastroenterol. 2009 Sep;54(3):196-8 [19844158.001]
  • (PMID = 19844152.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


57. Salama M, Ormonde D, Quach T, Ee H, Yusoff I: Outcomes of endoscopic resection of large colorectal neoplasms: an Australian experience. J Gastroenterol Hepatol; 2010 Jan;25(1):84-9
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes of endoscopic resection of large colorectal neoplasms: an Australian experience.
  • BACKGROUND AND AIMS: Endoscopic resection of large colorectal neoplasms is increasingly being used as an alternative to surgery.
  • The aim of the study was to report short- and long-term outcomes from endoscopic resection of large colorectal neoplasms from a single centre and use a model to predict mortality had surgery been performed.
  • METHODS: Consecutive patients referred for endoscopic resection of large (> or = 20 mm) colorectal neoplasms from January 2001 to February 2008 were included.
  • The Colorectal-POSSUM score was used to estimate mortality from open surgery.
  • RESULTS: There were 154 large neoplasms in 140 patients.
  • Mean neoplasm size was 26 mm (range 20-80 mm, 24 > or = 40 mm).
  • CONCLUSION: Endoscopic resection of large colorectal neoplasms is safe and effective even for very large benign neoplasms.
  • [MeSH-major] Colectomy. Colonoscopy. Colorectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19793173.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


58. Togashi K, Shimura K, Konishi F, Miyakura Y, Koinuma K, Horie H, Yasuda Y: Prospective observation of small adenomas in patients after colorectal cancer surgery through magnification chromocolonoscopy. Dis Colon Rectum; 2008 Feb;51(2):196-201
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective observation of small adenomas in patients after colorectal cancer surgery through magnification chromocolonoscopy.
  • PURPOSE: This study was designed to confirm the safety of not removing small adenoma in patients who undergo colorectal cancer surgery.
  • Benign adenomas of 6 mm or less in size, diagnosed based on both nonmagnified and magnified observation, were left unresected with a maximum of three polyps per patient.
  • CONCLUSIONS: Leaving small polyps is safe even in patients who have undergone colorectal cancer surgery, provided that careful observation is guaranteed.
  • [MeSH-major] Adenoma / diagnosis. Colonic Polyps / surgery. Colonoscopy / methods. Digestive System Surgical Procedures / methods. Neoplasms, Second Primary / diagnosis. Postoperative Care / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Prospective Studies. Reoperation


59. Holten-Andersen MN, Hansen U, Brünner N, Nielsen HJ, Illemann M, Nielsen BS: Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma. Int J Cancer; 2005 Jan 10;113(2):198-206
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localization of tissue inhibitor of metalloproteinases 1 (TIMP-1) in human colorectal adenoma and adenocarcinoma.
  • We have previously demonstrated that TIMP-1 is elevated in blood from colorectal cancer patients and that high TIMP-1 levels predict poor prognosis.
  • To clarify the role of TIMP-1 in colorectal tumorigenesis, the expression pattern of TIMP-1 in benign and malignant colorectal tumors was studied.
  • In all of 24 cases of colorectal adenocarcinoma TIMP-1 mRNA was detected by in situ hybridization.
  • No TIMP-1 mRNA was seen in any of the cases in benign or malignant epithelial cells, in vascular cells or smooth muscle cells.
  • In conclusion, TIMP-1 expression is a rare event in benign human colon tissue but is highly expressed by myofibroblasts in association with invading colon cancer cells.
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Adenoma / genetics. Adenoma / pathology. Colorectal Neoplasms / genetics. Colorectal Neoplasms / pathology. Tissue Inhibitor of Metalloproteinase-1 / biosynthesis. Tissue Inhibitor of Metalloproteinase-1 / pharmacology
  • [MeSH-minor] Case-Control Studies. Cell Transformation, Neoplastic. Diagnosis, Differential. Fibroblasts / physiology. Humans. Immunohistochemistry. In Situ Hybridization, Fluorescence. Neoplasm Invasiveness. RNA, Messenger / analysis. RNA, Messenger / biosynthesis

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15386409.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Tissue Inhibitor of Metalloproteinase-1
  •  go-up   go-down


60. Wierzbicki PM, Adrych K, Kartanowicz D, Dobrowolski S, Stanislawowski M, Chybicki J, Godlewski J, Korybalski B, Smoczynski M, Kmiec Z: Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer. J Physiol Pharmacol; 2009 Oct;60 Suppl 4:63-70
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fragile histidine triad (FHIT) gene is overexpressed in colorectal cancer.
  • AIM: To investigate loss of heterozygosity (LOH) at FRA3B, expression of FHIT gene at the mRNA and protein levels in sporadic colorectal carcinoma (CRC) and benign colon adenoma.
  • MATERIALS AND METHODS: FHIT mRNA was quantified by the validated realtime PCR (QPCR) in tumor samples of 84 CRC patients and mucosal biopsies of 15 adenomas, in comparison to 37 control patients, whereas subgroup of 57 CRC, 10 adenoma and 10 control cases were selected for immunohistochemical (IHC) detection of the native FHIT protein and LOH determination at FRA3B.
  • CONCLUSION: Our data suggest that reduction or absence of the FHIT gene expression is not a prerequisite for colorectal cancer development and progression.
  • [MeSH-major] Acid Anhydride Hydrolases / biosynthesis. Adenoma / metabolism. Colorectal Neoplasms / metabolism. Neoplasm Proteins / biosynthesis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20083853.001).
  • [ISSN] 1899-1505
  • [Journal-full-title] Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • [ISO-abbreviation] J. Physiol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / DNA Primers; 0 / Neoplasm Proteins; 0 / RNA, Messenger; 0 / fragile histidine triad protein; 63231-63-0 / RNA; EC 3.6.- / Acid Anhydride Hydrolases
  •  go-up   go-down


61. Tamura H, Ohtsuka M, Washiro M, Kimura F, Shimizu H, Yoshidome H, Kato A, Seki N, Miyazaki M: Reg IV expression and clinicopathologic features of gallbladder carcinoma. Hum Pathol; 2009 Dec;40(12):1686-92
MedlinePlus Health Information. consumer health - Gallbladder Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Regenerating islet-derived family, member 4 (Reg IV) has been shown to be associated with colorectal carcinogenesis and gastric carcinogenesis through intestinal metaplasia.
  • Before surgical resection, 4 (33%) of 12 patients with gallbladder carcinoma had high serum Reg IV levels, whereas Reg IV was never elevated in 12 patients with benign diseases.
  • The serum levels of Reg IV decreased after surgical resection of the tumors.
  • The serum level of Reg IV may be of use or indicative of neoplasia.
  • [MeSH-major] Adenocarcinoma / metabolism. Gallbladder Neoplasms / metabolism. Lectins, C-Type / biosynthesis
  • [MeSH-minor] Biomarkers, Tumor / analysis. Enzyme-Linked Immunosorbent Assay. Gene Expression. Homeodomain Proteins / biosynthesis. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Metaplasia / genetics. Metaplasia / metabolism. Metaplasia / pathology. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19716164.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Lectins, C-Type; 0 / REG4 protein, human
  •  go-up   go-down


62. Ooi BS, Quah HM, Fu CW, Eu KW: Laparoscopic high anterior resection with natural orifice specimen extraction (NOSE) for early rectal cancer. Tech Coloproctol; 2009 Mar;13(1):61-4
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Laparoscopic surgery for colorectal cancer requires an abdominal incision to extract the resected specimen.
  • The upper rectum distal to the tumour and proximal colon was transected with a laparoscopic stapler.
  • The rectal stump was transected again just below the opening to close off the stump, and the colorectal anastomosis was then completed intracorporeally.
  • This procedure may be applicable to benign tumours and early colorectal cancer, and serves as an intermediate step between laparoscopic and natural orifice surgery.
  • [MeSH-major] Colectomy / methods. Colon / surgery. Laparoscopy / methods. Polyps / surgery. Rectal Neoplasms / surgery. Rectum / surgery
  • [MeSH-minor] Anastomosis, Surgical. Colonoscopy. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19288243.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


63. Lin B, Utleg AG, Gravdal K, White JT, Halvorsen OJ, Lu W, True LD, Vessella R, Lange PH, Nelson PS, Hood L, Kalland KH, Akslen LA: WDR19 expression is increased in prostate cancer compared with normal cells, but low-intensity expression in cancers is associated with shorter time to biochemical failures and local recurrence. Clin Cancer Res; 2008 Mar 1;14(5):1397-406
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Prostate cancer is the third leading cause of cancer death in the United States, following lung and colorectal cancer.
  • Here, we evaluate its utility as a prostate cancer tissue marker for diagnosis and prognostic evaluation.
  • After generating antibodies against WDR19, tissue microarrays (TMA) were employed to compare WDR19 expression between normal, benign prostatic hyperplasia, and prostate cancer tissue.
  • Large-scale immunohistochemical staining using TMAs reveals a significant percentage of increase in intensely staining tissue cores in cancer tissue when compared with normal or benign prostatic hyperplastic tissue.
  • The continued expansion of a multiple-marker panel will conceivably increase the sensitivity and specificity of prostate cancer diagnosis and prognosis.

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18316561.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / P50 GM076547; United States / NIGMS NIH HHS / GM / 5P50GM076547; United States / NCI NIH HHS / CA / 5U54CA119347
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Proteins; 0 / RNA, Messenger; 0 / WDR19 protein, human; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


64. Yamauchi N, Watanabe A, Hishinuma M, Ohashi K, Midorikawa Y, Morishita Y, Niki T, Shibahara J, Mori M, Makuuchi M, Hippo Y, Kodama T, Iwanari H, Aburatani H, Fukayama M: The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma. Mod Pathol; 2005 Dec;18(12):1591-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Then, we evaluated the feasibility of GPC3-immunohistochemistry in the pathological diagnosis of benign and malignant hepatocellular lesions by applying these monoclonal antibodies to formalin-fixed and paraffin-embedded specimens.
  • GPC3 immunoreactivity was detected in only one of 23 metastatic lesions of colorectal carcinoma, and its expression was entirely absent in the liver cell adenoma (0/7), carcinoid tumor (0/1), and cholangiocellular carcinoma (0/16).
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Carcinoma, Hepatocellular / diagnosis. Heparan Sulfate Proteoglycans / metabolism. Liver Neoplasms / diagnosis
  • [MeSH-minor] Antibodies, Monoclonal / biosynthesis. Antibodies, Monoclonal / immunology. Cell Line, Tumor. Glypicans. Hepatoblastoma / metabolism. Hepatoblastoma / pathology. Hepatocytes / metabolism. Hepatocytes / pathology. Humans. Liver / embryology. Liver / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15920546.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Glypicans; 0 / Heparan Sulfate Proteoglycans
  •  go-up   go-down


65. Endreseth BH, Wibe A, Svinsås M, Mårvik R, Myrvold HE: Postoperative morbidity and recurrence after local excision of rectal adenomas and rectal cancer by transanal endoscopic microsurgery. Colorectal Dis; 2005 Mar;7(2):133-7
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Eight patients with benign pre-operative histopathological examination had cancer.
  • CONCLUSION: TEM is a safe technique well tolerated also by high-risk patients, and should be the preferred method in patients with benign tumours in the middle and upper part of the rectum, and in selected cases of early rectal cancer.
  • Benign pre-operative histology does not preclude malignancy and some patients may need further treatment for unexpected malignancy.
  • [MeSH-major] Adenoma / surgery. Microsurgery / methods. Proctoscopy / methods. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colonoscopy. Endosonography. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15720349.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


66. Galitskiĭ MV, Khomeriki SG, Nikiforov PA: [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy]. Eksp Klin Gastroenterol; 2009;(5):28-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of proliferation and apoptosis markers in neoplasms of colon mucosa after cholecystectomy].
  • The cholecystectomy results in change of cholic acids flow into intestine.
  • Permanent type of the bile flow provokes the increase of proliferation of colic epithelial cells and increases the risk for development of right-sided colorectal tumors.
  • Meanwhile morphological features of colorectal tumors at the patients with cholecystectomy are still remaining to be clarified.
  • The goal of the study was to investigate immunohistochemical markers of proliferation and apoptosis in colorectal adenomas and adenocarcinomas at the patients with cholecystectomy.
  • 83 tumors and 49 samples of mucosa were immunostained with monoclonal mouse anti-human p53 protein (Dako) and monoclonal mouse anti-human Ki-67 antigen (Novocastra).
  • Thus, in benign colorectal tumors at the patients with retained function of gallbladder intensifying of epithelial cells proliferation is not accompanied with intensifying of apoptosis, and in malignant tumors a complete supression of apoptosis is observed.
  • The retaining of apoptosis in colorectal tumors compensates intensive proliferative activity with expectation of better prognosis.
  • [MeSH-major] Apoptosis. Biomarkers, Tumor / biosynthesis. Cell Proliferation. Cholecystectomy. Colon / metabolism. Colonic Neoplasms / metabolism. Gene Expression Regulation, Neoplastic. Intestinal Mucosa / metabolism. Ki-67 Antigen / biosynthesis. Tumor Suppressor Protein p53 / biosynthesis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20205327.001).
  • [ISSN] 1682-8658
  • [Journal-full-title] Ėksperimental'nai︠a︡ i klinicheskai︠a︡ gastroėnterologii︠a︡ = Experimental & clinical gastroenterology
  • [ISO-abbreviation] Eksp Klin Gastroenterol
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


67. Clausen OP, Aass HC, Beigi M, Purdie KJ, Proby CM, Brown VL, Mattingsdal M, Micci F, Kølvraa S, Bolund L, Deangelis PM: Are keratoacanthomas variants of squamous cell carcinomas? A comparison of chromosomal aberrations by comparative genomic hybridization. J Invest Dermatol; 2006 Oct;126(10):2308-15
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Keratoacanthoma (KA) is a benign keratinocytic neoplasm that usually presents as a solitary nodule on sun-exposed areas, develops within 6-8 weeks and spontaneously regresses after 3-6 months.
  • The patterns of recurrent aberrations were also different in the two types of neoplasms, pointing to different genetic mechanisms involved in their developments.
  • [MeSH-major] Carcinoma, Squamous Cell / genetics. Chromosome Aberrations. Keratoacanthoma / genetics. Nucleic Acid Hybridization / methods. Skin Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dermatology. 1999;199(3):208-12 [10592399.001]
  • [Cites] Br J Dermatol Syph. 1950 Jul-Aug;62(7-8):310-3 [24538027.001]
  • [Cites] Int J Colorectal Dis. 2001 Feb;16(1):38-45 [11317696.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):4115-22 [12124350.001]
  • [Cites] Int J Cancer. 2002 Nov 20;102(3):300-3 [12397655.001]
  • [Cites] J Invest Dermatol. 2002 Dec;119(6):1367-72 [12485441.001]
  • [Cites] Arch Dermatol. 2003 Jul;139(7):876-82 [12873882.001]
  • [Cites] Genes Chromosomes Cancer. 2003 Oct;38(2):137-48 [12939741.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):468-75 [14976535.001]
  • [Cites] Br J Surg. 1967 Mar;54(3):191-5 [6020987.001]
  • [Cites] Birth Defects Orig Artic Ser. 1971 Jun;7(8):157-63 [5173258.001]
  • [Cites] Australas J Dermatol. 1979 Apr;20(1):34-40 [475695.001]
  • [Cites] Science. 1992 Oct 30;258(5083):818-21 [1359641.001]
  • [Cites] Am J Dermatopathol. 1993 Aug;15(4):332-42; discussion 343-52 [8214391.001]
  • [Cites] J Am Acad Dermatol. 1994 Jan;30(1):1-19; quiz 20-2 [8277007.001]
  • [Cites] Arch Dermatol. 1994 Feb;130(2):181-6 [8304756.001]
  • [Cites] Cancer Res. 1994 Aug 15;54(16):4257-60 [8044767.001]
  • [Cites] Cancer Res. 1994 Sep 1;54(17):4756-9 [8062275.001]
  • [Cites] Lancet. 1994 Sep 17;344(8925):788-9 [7916075.001]
  • [Cites] Genes Chromosomes Cancer. 1994 Aug;10(4):231-43 [7522536.001]
  • [Cites] Br J Cancer. 1996 Mar;73(5):649-53 [8605102.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Apr;15(4):234-45 [8703849.001]
  • [Cites] Trends Genet. 1997 Oct;13(10):405-9 [9351342.001]
  • [Cites] Int J Dermatol. 1998 Sep;37(9):677-81 [9762818.001]
  • [Cites] Lab Invest. 1999 Feb;79(2):111-22 [10068200.001]
  • [Cites] J Cutan Pathol. 1999 Apr;26(4):183-9 [10335895.001]
  • [Cites] Br J Cancer. 1999 May;80(3-4):526-35 [10408863.001]
  • [Cites] Eur Urol. 2005 Jan;47(1):58-63 [15582250.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jul;43(3):239-48 [15834942.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1250-4 [11245413.001]
  • (PMID = 16728973.001).
  • [ISSN] 0022-202X
  • [Journal-full-title] The Journal of investigative dermatology
  • [ISO-abbreviation] J. Invest. Dermatol.
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / CRUK/ A6695
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2423224; NLM/ UKMS1915
  •  go-up   go-down


68. Mittal R, Perakath B, Chase S, Jesudason MR, Nayak S: Transanal excision of anorectal lesions--a single centre experience. Trop Gastroenterol; 2010 Jan-Mar;31(1):65-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Patients were divided into three groups. (1) Resection for benign disease (2) Curative and (3) Palliative resection for malignant disease.
  • RESULTS: Forty six patients underwent transanal excision, 21 for benign and 25 for malignant disease, 20 with curative and 5 with palliative intent.
  • Tubulovillous adenomas and hyperplastic polyps were the commonest benign lesions.
  • CONCLUSION: Transanal excision, when technically feasible, remains the treatment of choice for benign disease of the rectum.
  • [MeSH-major] Rectal Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Palliative Care. Postoperative Complications. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20860237.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


69. Bui MM, Draper NL, Dessureault S, Nasir NA, Cooper H, Nasir A, Coppola D: Colonic angiolymphoid hyperplasia with eosinophilia masquerading as malignancy: a case report and review of the literature. Clin Colorectal Cancer; 2010 Jul;9(3):179-82
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Whether AHE is a reactive process or a neoplastic process (either a benign vascular neoplasm or a T-cell lymphoproliferative disorder) is still under debate.
  • [MeSH-major] Angiolymphoid Hyperplasia with Eosinophilia / pathology. Colonic Diseases / pathology. Colonic Neoplasms / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Head and Neck Neoplasms / complications. Hemangioma / complications. Humans. Ovarian Neoplasms / complications

  • MedlinePlus Health Information. consumer health - Colonic Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20643624.001).
  • [ISSN] 1938-0674
  • [Journal-full-title] Clinical colorectal cancer
  • [ISO-abbreviation] Clin Colorectal Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


70. van Baardewijk LJ, Idenburg FJ, Clahsen PC, Möllers MJ: [Von Meyenburg complexes in the liver: not metastases]. Ned Tijdschr Geneeskd; 2010;154:A1674
MedlinePlus Health Information. consumer health - Liver Diseases.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • VMCs, also called biliary hamartomas, are rare and benign malformations of the bile ducts.
  • Intraoperative frozen section analysis to differentiate between malignant and benign lesions has a sensitivity of 97% and a specificity of 99%.
  • The benign nature of VMCs means that they do not require treatment.
  • The patient underwent total mesorectal excision and follow-up after 3, 7 and 9 months did not reveal any indications of recurrent colorectal cancer or metastases.
  • [MeSH-major] Hamartoma / diagnosis. Liver Diseases / diagnosis. Liver Neoplasms / diagnosis
  • [MeSH-minor] Aged. Bile Ducts / abnormalities. Bile Ducts / pathology. Carcinoma / pathology. Carcinoma / surgery. Diagnosis, Differential. Female. Humans. Incidental Findings. Liver / pathology. Neoplasm Metastasis / diagnosis. Neoplasm Metastasis / pathology. Rectal Neoplasms / pathology. Rectal Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20619020.001).
  • [ISSN] 1876-8784
  • [Journal-full-title] Nederlands tijdschrift voor geneeskunde
  • [ISO-abbreviation] Ned Tijdschr Geneeskd
  • [Language] dut
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


71. Jones S, Chen WD, Parmigiani G, Diehl F, Beerenwinkel N, Antal T, Traulsen A, Nowak MA, Siegel C, Velculescu VE, Kinzler KW, Vogelstein B, Willis J, Markowitz SD: Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A; 2008 Mar 18;105(11):4283-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative lesion sequencing provides insights into tumor evolution.
  • We show that the times separating the birth of benign, invasive, and metastatic tumor cells can be determined by analysis of the mutations they have in common.
  • When combined with prior clinical observations, these analyses suggest the following general conclusions about colorectal tumorigenesis: (i) It takes approximately 17 years for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cancer to acquire the ability to metastasize;.
  • (iii) the process of cell culture ex vivo does not introduce new clonal mutations into colorectal tumor cell populations; and (iv) the rates at which point mutations develop in advanced cancers are similar to those of normal cells.
  • These results have important implications for understanding human tumor pathogenesis, particularly those associated with metastasis.

  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 4;100(3):776-81 [12552134.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11476-9; discussion 11479-80 [18089773.001]
  • [Cites] World J Surg. 2004 Mar;28(3):263-70 [14961200.001]
  • [Cites] J Natl Cancer Inst. 2004 Oct 6;96(19):1420-5 [15467030.001]
  • [Cites] Humangenetik. 1972;16(1):87-110 [4647448.001]
  • [Cites] Cancer. 1975 Dec;36(6):2251-70 [1203876.001]
  • [Cites] Br J Cancer. 1982 Nov;46(5):773-81 [7171456.001]
  • [Cites] Cancer Res. 1983 Apr;43(4):1650-5 [6299526.001]
  • [Cites] N Engl J Med. 1988 Sep 1;319(9):525-32 [2841597.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6109-14 [3167857.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Cytometry. 1989 Nov;10(6):673-80 [2684578.001]
  • [Cites] Br J Cancer. 1990 Mar;61(3):382-4 [2328202.001]
  • [Cites] Int J Cancer. 1990 May 15;45(5):968-71 [2159442.001]
  • [Cites] Cell. 1990 Jun 1;61(5):759-67 [2188735.001]
  • [Cites] Cancer Res. 1990 Dec 1;50(23):7717-22 [2253215.001]
  • [Cites] Br J Surg. 1991 Jan;78(1):60-6 [1998868.001]
  • [Cites] Science. 1995 Jun 2;268(5215):1336-8 [7761852.001]
  • [Cites] Br J Cancer. 1995 Aug;72(2):435-41 [7640229.001]
  • [Cites] Nat Genet. 1996 Jul;13(3):343-6 [8673134.001]
  • [Cites] Cell. 1996 Oct 18;87(2):159-70 [8861899.001]
  • [Cites] Cytometry. 1997 Nov 1;29(3):273-8 [9389445.001]
  • [Cites] Biochim Biophys Acta. 1998 Oct 1;1400(1-3):213-22 [9748584.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):803-11 [10091757.001]
  • [Cites] Eur J Surg Oncol. 1999 Jun;25(3):292-6 [10336810.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1963 Oct;90:673-87 [14068399.001]
  • [Cites] Cell Cycle. 2004 Oct;3(10):1221-4 [15467468.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8111-7 [16166284.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):610-4 [16582617.001]
  • [Cites] Cancer Sci. 2006 May;97(5):362-7 [16630132.001]
  • [Cites] Nat Methods. 2006 Jul;3(7):551-9 [16791214.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Arch Surg. 2006 Dec;141(12):1220-6; discussion 1227 [17178965.001]
  • [Cites] Curr Biol. 2007 Apr 3;17(7):R233-6 [17407749.001]
  • [Cites] Nat Protoc. 2006;1(2):859-69 [17406318.001]
  • [Cites] Science. 2007 Nov 16;318(5853):1108-13 [17932254.001]
  • [Cites] Cancer Res. 2007 Dec 15;67(24):11471-5 [18089772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8817-22 [12857956.001]
  • (PMID = 18337506.001).
  • [ISSN] 1091-6490
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA57345; United States / NCI NIH HHS / CA / R37 CA043460; United States / NCI NIH HHS / CA / R01 CA127306; United States / NCI NIH HHS / CA / CA121113; United States / NIGMS NIH HHS / GM / GM078986; United States / NCI NIH HHS / CA / CA127306; United States / NCI NIH HHS / CA / P50 CA062924; United States / NIGMS NIH HHS / GM / R01 GM078986; United States / NCI NIH HHS / CA / CA62924; United States / NCI NIH HHS / CA / R01 CA120237; United States / NCI NIH HHS / CA / R01 CA121113; United States / NIGMS NIH HHS / GM / GM078986-02; United States / NCI NIH HHS / CA / P30 CA043703; United States / NCI NIH HHS / CA / CA43460; United States / NCI NIH HHS / CA / CA043703; United States / NCI NIH HHS / CA / CA120237; United States / NCI NIH HHS / CA / U54 CA116867; United States / NIGMS NIH HHS / GM / R01 GM078986-02; United States / NCI NIH HHS / CA / CA116867; United States / Howard Hughes Medical Institute / / ; United States / NCI NIH HHS / CA / R37 CA057345; United States / NCI NIH HHS / CA / R01 CA057345; United States / NCI NIH HHS / CA / R01 CA105090
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 9007-49-2 / DNA
  • [Other-IDs] NLM/ PMC2393770
  •  go-up   go-down


72. Liu W, Wei W, Winer D, Bamberger AM, Bamberger C, Wagener C, Ezzat S, Asa SL: CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene; 2007 Apr 26;26(19):2747-58
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CEACAM1 is a putative tumor suppressor based on diminished expression in some solid neoplasms such as colorectal carcinoma.
  • However, CEACAM1 is overexpressed in some tumors such as non-small cell lung cancer.
  • CEACAM1 is expressed in thyroid carcinoma cell lines derived from tumors that exhibit aggressive behavior.
  • Forced CEACAM1 expression enhanced cell-matrix adhesion and migration and promoted tumor invasiveness.
  • Conversely, small interfering RNA (siRNA)-mediated downregulation of CEACAM1 expression in MRO cells accelerated cell cycle progression and significantly enhanced tumor size in xenografted mice.
  • CEACAM1 is not appreciably expressed in normal thyroid tissue or benign thyroid tumors.
  • In a human thyroid tissue array, CEACAM1 reactivity was associated with metastatic spread but not with increased tumor size.
  • These findings identify CEACAM1 as a unique mediator that restricts tumor growth whereas increasing metastatic potential.
  • [MeSH-major] Antigens, CD / physiology. Carcinoembryonic Antigen / metabolism. Cell Adhesion Molecules / physiology. Cell Proliferation. Thyroid Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma, Follicular / metabolism. Adenocarcinoma, Follicular / pathology. Adult. Aged. Animals. Carcinoma / metabolism. Carcinoma / pathology. Cell Line, Tumor. Cyclin-Dependent Kinase Inhibitor p21 / genetics. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Cyclin-Dependent Kinase Inhibitor p27 / genetics. Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Female. Gene Expression Regulation, Neoplastic. Gene Silencing. Humans. Male. Mice. Mice, SCID. Middle Aged. Neoplasm Invasiveness. RNA, Small Interfering / pharmacology

  • Genetic Alliance. consumer health - Thyroid Cancer.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17057731.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / CD66 antigens; 0 / CDKN1A protein, human; 0 / Carcinoembryonic Antigen; 0 / Ceacam1 protein, mouse; 0 / Cell Adhesion Molecules; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / RNA, Small Interfering; 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27
  •  go-up   go-down


73. Willis S, Schumpelick V: [Open colon surgery]. Chirurg; 2005 Nov;76(11):1073-81
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In case of benign underlying disease, the operational method depends largely on the extent to which the intestine is affected and can include anything from simple colotomy and polyp removal to colectomy for toxic megacolon.
  • [MeSH-major] Colectomy / methods. Colorectal Neoplasms / surgery. Lymph Node Excision / methods. Sigmoid Neoplasms / surgery
  • [MeSH-minor] Anastomosis, Surgical / methods. Colon / pathology. Colonic Polyps / mortality. Colonic Polyps / pathology. Colonic Polyps / surgery. Humans. Neoplasm Invasiveness / pathology. Neoplasm Staging. Postoperative Complications / mortality. Surgical Staplers. Surgical Wound Dehiscence / mortality. Survival Analysis. Suture Techniques

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1988 May;75(5):409-15 [3292002.001]
  • [Cites] Dis Colon Rectum. 2004 Mar;47(3):271-7; discussion 277-8 [14991487.001]
  • [Cites] Dis Colon Rectum. 1990 Jul;33(7):610-4 [2361432.001]
  • [Cites] Dis Colon Rectum. 1994 Jul;37(7):651-9 [8026230.001]
  • [Cites] Chirurg. 2004 Nov;75(11):1071-8 [15316639.001]
  • (PMID = 16240155.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


74. Wang Q, Xie R, Zhang QY: [Clinical significance of plasma fibrinogen level in patients with colorectal cancer]. Zhonghua Zhong Liu Za Zhi; 2005 Sep;27(9):544-6
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of plasma fibrinogen level in patients with colorectal cancer].
  • OBJECTIVE: To investigate correlation of plasma level of fibrinogen with clinical stage, depth of invasion and metastasis of colorectal cancer, and its diagnostic and prognostic significance.
  • METHODS: The present study included 229 patients suffering from colorectal cancer and 31 cases with benign colorectal diseases.
  • The tumor markers CEA, CA19-9 and CA72-4 were examined by electrochemiluminescence immunoassay on Roche Eleccsys 2010 analyzer.
  • Tumor makers CA242 and TPS were tested by ELISA.
  • RESULTS: The fibrinogen level was increased in patients with colorectal cancer compared to that in patients with benign colorectal diseases.
  • It increased with the clinical stage and depth of tumor invasion.
  • There were positive correlations of fibrinogen level with tumor makers CEA, CA242 and TPS, but not with CA19-9 and CA72-4.
  • CONCLUSION: Plasma fibrinogen is significantly increased in colorectal carcinoma patients with progression of the disease.
  • [MeSH-major] Adenocarcinoma / blood. Colorectal Neoplasms / blood. Fibrinogen / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antigens, Tumor-Associated, Carbohydrate / blood. Carcinoembryonic Antigen / blood. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Peptides / blood

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438853.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Tumor-Associated, Carbohydrate; 0 / CA 242 antigen; 0 / Carcinoembryonic Antigen; 0 / Peptides; 0 / tissue polypeptide specific antigen; 9001-32-5 / Fibrinogen
  •  go-up   go-down


75. Ogawa K, Utsunomiya T, Mimori K, Tanaka F, Inoue H, Nagahara H, Murayama S, Mori M: Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer. Clin Cancer Res; 2005 Apr 15;11(8):2889-93
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of human kallikrein gene 6 messenger RNA expression in colorectal cancer.
  • The purpose of the current study was to quantify the expression of KLK6 in malignant and benign colorectal tissues and to statistically analyze whether KLK6 expression levels correlate with clinicopathologic variables and prognosis in patients with colorectal cancer.
  • EXPERIMENTAL DESIGNS: Paired colorectal tissue samples from cancerous and corresponding noncancerous tissues were obtained from 63 patients with colorectal cancer who underwent surgical resection.
  • CONCLUSIONS: The results of this study indicated that KLK6 mRNA expression was significantly higher in cancerous than in noncancerous colorectal tissues, and high expression of KLK6 mRNA correlated with serosal invasion, liver metastasis, advanced Duke's stage, and a poor prognosis for patients with colorectal cancer.
  • [MeSH-major] Colorectal Neoplasms / pathology. Kallikreins / genetics. RNA, Messenger / metabolism
  • [MeSH-minor] Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Reverse Transcriptase Polymerase Chain Reaction. Survival Analysis

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15837738.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; EC 3.4.21.- / KLK6 protein, human; EC 3.4.21.- / Kallikreins
  •  go-up   go-down


76. Whitehouse PA, Tilney HS, Armitage JN, Simson JN: Transanal endoscopic microsurgery: risk factors for local recurrence of benign rectal adenomas. Colorectal Dis; 2006 Nov;8(9):795-9
MedlinePlus Health Information. consumer health - Endoscopy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transanal endoscopic microsurgery: risk factors for local recurrence of benign rectal adenomas.
  • OBJECTIVE: Transanal endoscopic microsurgery (TEM) is a minimally invasive technique for excision of selected benign and malignant rectal neoplasms.
  • It is considered a safe and effective treatment but recurrence rates of 1-13% are reported for benign lesions.
  • The aim of this study was to assess risk factors for local recurrence of benign rectal lesions and to evaluate mortality and morbidity following TEM.
  • METHOD: Data were prospectively collected from all patients undergoing TEM for benign adenomas from January 1998 to March 2005.
  • CONCLUSION: TEM is a safe and effective treatment for benign rectal adenomas.
  • [MeSH-major] Adenoma / surgery. Endoscopy / methods. Microsurgery / methods. Neoplasm Recurrence, Local. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Colorectal Dis. 2006 Nov;8(9):731-2 [17032317.001]
  • (PMID = 17032328.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


77. Milot L, Guindi M, Gallinger S, Moulton CA, Brock KK, Dawson LA, Haider MA: MR imaging correlates of intratumoral tissue types within colorectal liver metastases: a high-spatial-resolution fresh ex vivo radiologic-pathologic correlation study. Radiology; 2010 Mar;254(3):747-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MR imaging correlates of intratumoral tissue types within colorectal liver metastases: a high-spatial-resolution fresh ex vivo radiologic-pathologic correlation study.
  • PURPOSE: To analyze the direct relationship between complex internal magnetic resonance (MR) signal intensity (SI) patterns observed in colorectal liver metastases and their microscopic tissue characteristics.
  • In seven consecutive patients undergoing hepatic resection for liver metastases (primary colorectal in six, breast mistaken for colorectal in one), the resected fresh ex vivo liver specimen was examined with T1-weighted (repetition time msec/echo time msec, 9/4.4-4.8) and T2-weighted (2500/90) MR imaging by using a voxel size of 0.47 x 0.7 x 2 mm.
  • CONCLUSION: IAN seen in colorectal metastases exhibits high T1-weighted SI and mixed T2-weighted SI.
  • This SI pattern is unusual for common benign liver lesions and may be helpful in the MR imaging diagnosis of colorectal liver metastases. (c) RSNA, 2010.
  • [MeSH-major] Colorectal Neoplasms / pathology. Liver Neoplasms / diagnosis. Liver Neoplasms / secondary. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Aged. Female. Humans. In Vitro Techniques. Linear Models. Male. Middle Aged. Neoplasm Staging. Prospective Studies

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20123902.001).
  • [ISSN] 1527-1315
  • [Journal-full-title] Radiology
  • [ISO-abbreviation] Radiology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


78. Smith A, Young GP, Cole SR, Bampton P: Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia. Cancer; 2006 Nov 1;107(9):2152-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of a brush-sampling fecal immunochemical test for hemoglobin with a sensitive guaiac-based fecal occult blood test in detection of colorectal neoplasia.
  • The current study was conducted to undertake a paired comparison of a sensitive guaiac FOBT (GFOBT; Hemoccult II Sensa, Beckman Coulter, Fullerton, CA) with a brush-sampling FIT (InSure; Enterix, North Ryde, NSW, Australia), to determine whether this FIT improves detection of significant neoplasia.
  • Paired comparison of positivity rates was undertaken in those found to have cancer and/or significant adenoma (high-grade dysplasia, villous change, > or =10 mm, serrated histology or > or =3 polyps), benign pathology, or no pathology.
  • In analyses of just the screening cohort, the FIT remained significantly better at detecting cancers and significant adenomas; the false-positive rate for any neoplasia was marginally higher with the FIT than the GFOBT (3.4% vs. 2.5%; 95% CI of difference, 0-1.8%), whereas positive predictive values were 41.9% and 40.4%, respectively.
  • As such, it should deliver greater reductions in colorectal cancer mortality and incidence than the GFOBT.
  • [MeSH-major] Adenoma / diagnosis. Colorectal Neoplasms / diagnosis. Feces / chemistry. Guaiac. Hemoglobins / analysis. Occult Blood
  • [MeSH-minor] Aged. Australia / epidemiology. Cohort Studies. False Positive Reactions. Female. Humans. Immunochemistry. Indicators and Reagents. Male. Mass Screening / methods. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Bowel Movement.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. GUM GUAIAC .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 American Cancer Society.
  • [CommentIn] Cancer. 2007 May 1;109(9):1925-6; author reply 1926 [17370313.001]
  • (PMID = 16998938.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Hemoglobins; 0 / Indicators and Reagents; 9000-29-7 / Guaiac
  •  go-up   go-down


79. Obtulowicz T, Swoboda M, Speina E, Gackowski D, Rozalski R, Siomek A, Janik J, Janowska B, Ciesla JM, Jawien A, Banaszkiewicz Z, Guz J, Dziaman T, Szpila A, Olinski R, Tudek B: Oxidative stress and 8-oxoguanine repair are enhanced in colon adenoma and carcinoma patients. Mutagenesis; 2010 Sep;25(5):463-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In the examined groups of patients with colorectal cancer (CRC, n = 89), benign adenoma (AD, n = 77) and healthy volunteers (controls, n = 99), we measured: vitamins A, C and E in blood plasma, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxodG) and 8-oxo-7,8-dihydroguanine (8-oxoGua) in leukocytes and urine, leukocyte 8-oxoGua excision activity, mRNA levels of APE1, OGG1, 8-oxo-7,8-dihydrodeoxyguanosine 5'-triphosphate pyrophosphohydrolase (MTH1) and OGG1 polymorphism.
  • [MeSH-major] Adenoma / metabolism. Carcinoma / metabolism. Colonic Neoplasms / metabolism. DNA Repair / genetics. Deoxyguanosine / analogs & derivatives. Oxidative Stress / genetics
  • [MeSH-minor] Adenomatous Polyps / blood. Adenomatous Polyps / metabolism. Adult. Aged. Aging / genetics. Antioxidants / metabolism. Case-Control Studies. DNA Glycosylases / genetics. DNA Glycosylases / metabolism. DNA Repair Enzymes / genetics. DNA Repair Enzymes / metabolism. DNA, Neoplasm / metabolism. DNA-(Apurinic or Apyrimidinic Site) Lyase / genetics. DNA-(Apurinic or Apyrimidinic Site) Lyase / metabolism. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. Neoplasm Staging. Phosphoric Monoester Hydrolases / genetics. Phosphoric Monoester Hydrolases / metabolism. Polymorphism, Single Nucleotide / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. Sex Characteristics. Smoking / adverse effects. Smoking / genetics

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534734.001).
  • [ISSN] 1464-3804
  • [Journal-full-title] Mutagenesis
  • [ISO-abbreviation] Mutagenesis
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antioxidants; 0 / DNA, Neoplasm; 0 / RNA, Messenger; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.1.3.- / Phosphoric Monoester Hydrolases; EC 3.1.6.- / 8-oxodGTPase; EC 3.2.2.- / DNA Glycosylases; EC 3.2.2.- / oxoguanine glycosylase 1, human; EC 4.2.99.18 / APEX1 protein, human; EC 4.2.99.18 / DNA-(Apurinic or Apyrimidinic Site) Lyase; EC 6.5.1.- / DNA Repair Enzymes; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


80. Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, Marks J, Godwin A, Gorelik E, Jacobs I, Menon U, Lu K, Badgwell D, Bast RC Jr, Lokshin AE: Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol; 2010 May 1;28(13):2159-66
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Ninety-six serum biomarkers were analyzed in sera from healthy women and from patients with ovarian cancer, benign pelvic tumors, and breast, colorectal, and lung cancers, using multiplex xMAP bead-based immunoassays.
  • This panel was selective for ovarian cancer showing SN of 33% for benign pelvic disease, SN of 6% for breast cancer, SN of 0% for colorectal cancer, and SN of 36% for lung cancer.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 2000 Jan-Feb;20(1B):569-72 [10769727.001]
  • [Cites] Cancer Res. 2000 Apr 15;60(8):2190-6 [10786683.001]
  • [Cites] Cancer Chemother Biol Response Modif. 1999;18:418-34 [10800496.001]
  • [Cites] Eur J Gynaecol Oncol. 2000;21(2):135-40 [10843471.001]
  • [Cites] Semin Surg Oncol. 2000 Jul-Aug;19(1):3-10 [10883018.001]
  • [Cites] Life Sci. 2001 Jan 12;68(8):861-72 [11213356.001]
  • [Cites] Curr Opin Obstet Gynecol. 2001 Feb;13(1):61-4 [11176234.001]
  • [Cites] Br J Cancer. 2001 Mar 2;84(5):643-50 [11237385.001]
  • [Cites] Clin Cancer Res. 2001 Aug;7(8):2380-6 [11489816.001]
  • [Cites] Int J Gynecol Cancer. 2001 Jul-Aug;11(4):277-82 [11520365.001]
  • [Cites] Cancer. 2001 Dec 1;92(11):2837-44 [11753957.001]
  • [Cites] Cancer Treat Res. 2002;107:247-58 [11775453.001]
  • [Cites] Curr Oncol Rep. 2002 Mar;4(2):165-74 [11822989.001]
  • [Cites] Mol Pathol. 2002 Apr;55(2):110-20 [11950960.001]
  • [Cites] Tumour Biol. 2002 May-Jun;23(3):185-92 [12218299.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):103-13 [12582019.001]
  • [Cites] Clin Biochem. 2003 Mar;36(2):135-43 [12633763.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1035-43 [12637468.001]
  • [Cites] J Clin Oncol. 2003 May 15;21(10 Suppl):194s-199s [12743134.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2771-4 [12782581.001]
  • [Cites] Cancer Res. 2003 Jul 1;63(13):3695-700 [12839961.001]
  • [Cites] Int J Cancer. 2003 Sep 10;106(4):605-10 [12845660.001]
  • [Cites] Am Fam Physician. 2003 Sep 15;68(6):1075-82 [14524394.001]
  • [Cites] Fertil Steril. 2003 Oct;80(4):1068-9; author reply 1069-70 [14556841.001]
  • [Cites] Biomed Pharmacother. 2004 Jan;58(1):24-38 [14739059.001]
  • [Cites] Mol Cell Proteomics. 2004 Apr;3(4):355-66 [14764655.001]
  • [Cites] Hum Reprod. 2005 Jan;20(1):117-21 [15513972.001]
  • [Cites] Int J Oncol. 2005 Feb;26(2):379-84 [15645122.001]
  • [Cites] J Endocrinol Invest. 2004 Jun;27(6):528-34 [15717649.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7 [15824174.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2005 May 1;120(1):87-90 [15866092.001]
  • [Cites] Aust N Z J Obstet Gynaecol. 2005 Jun;45(3):211-4 [15904446.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7677-82 [15890779.001]
  • [Cites] Gastroenterology. 2005 Aug;129(2):464-75 [16083703.001]
  • [Cites] J Clin Oncol. 2005 Nov 1;23(31):7919-26 [16258091.001]
  • [Cites] Crit Rev Clin Lab Sci. 2004;41(3):265-312 [15307634.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5882-90 [15313933.001]
  • [Cites] Gynecol Oncol. 2004 Oct;95(1):9-15 [15385104.001]
  • [Cites] J Clin Oncol. 2004 Oct 15;22(20):4059-66 [15381683.001]
  • [Cites] Cancer. 1975 May;35(5):1377-81 [47262.001]
  • [Cites] Br J Obstet Gynaecol. 1979 Nov;86(11):901-4 [116672.001]
  • [Cites] N Engl J Med. 1983 Oct 13;309(15):883-7 [6310399.001]
  • [Cites] Biomed Biochim Acta. 1986;45(3):371-84 [3518711.001]
  • [Cites] Gynecol Oncol. 1988 Jan;29(1):66-75 [3422208.001]
  • [Cites] Gynecol Oncol. 1988 Jun;30(2):265-73 [3163666.001]
  • [Cites] Hum Reprod. 1989 Jan;4(1):1-12 [2651469.001]
  • [Cites] J Cancer Res Clin Oncol. 1989;115(5):456-8 [2808485.001]
  • [Cites] Gene. 1999 Oct 1;238(2):375-85 [10570965.001]
  • [Cites] Br J Obstet Gynaecol. 1992 Apr;99(4):329-32 [1581280.001]
  • [Cites] Br J Cancer. 1993 Jul;68(1):122-4 [7686390.001]
  • [Cites] Tumour Biol. 1993;14(2):105-15 [8392219.001]
  • [Cites] J Natl Cancer Inst. 1993 Nov 3;85(21):1748-51 [8411259.001]
  • [Cites] Br J Obstet Gynaecol. 1993 Dec;100(12):1120-4 [8297846.001]
  • [Cites] Eur J Clin Chem Clin Biochem. 1994 Mar;32(3):201-7 [8031969.001]
  • [Cites] Semin Surg Oncol. 1994 Jul-Aug;10(4):242-8 [8091065.001]
  • [Cites] Br J Cancer. 1994 Dec;70(6):1186-7 [7981074.001]
  • [Cites] Anticancer Res. 1994 Nov-Dec;14(6B):2743-6 [7532929.001]
  • [Cites] Cancer Invest. 1995;13(2):227-38 [7874576.001]
  • [Cites] JAMA. 1995 Dec 27;274(24):1926-30 [8568986.001]
  • [Cites] Acta Obstet Gynecol Scand. 1997 Mar;76(3):283-5 [9093148.001]
  • [Cites] Gynecol Oncol. 1997 Jul;66(1):27-30 [9234916.001]
  • [Cites] Br J Obstet Gynaecol. 1997 Sep;104(9):1024-9 [9307529.001]
  • [Cites] Anticancer Res. 1997 Nov-Dec;17(6D):4735-7 [9494598.001]
  • [Cites] Eur J Cancer Prev. 1998 Feb;7(1):23-35 [9511849.001]
  • [Cites] Gynecol Oncol. 1998 Jun;69(3):248-52 [9648596.001]
  • [Cites] Anticancer Res. 1998 Jul-Aug;18(4B):2891-4 [9713482.001]
  • [Cites] Ann Acad Med Singapore. 1998 Sep;27(5):676-82 [9919339.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 1999 Feb;8(2):129-37 [10067810.001]
  • [Cites] Lancet. 1999 Apr 10;353(9160):1207-10 [10217079.001]
  • [Cites] Clin Exp Metastasis. 1999 Mar;17(2):131-40 [10411105.001]
  • [Cites] Gynecol Obstet Invest. 1999;48(2):133-7 [10461006.001]
  • [Cites] J Clin Endocrinol Metab. 1999 Sep;84(9):3030-5 [10487660.001]
  • [Cites] Gynecol Oncol. 2005 Dec;99(3):656-63 [16112717.001]
  • [Cites] Int J Gynecol Cancer. 2005 Nov-Dec;15 Suppl 3:274-81 [16343244.001]
  • [Cites] Clin Sci (Lond). 2006 Mar;110(3):279-91 [16464170.001]
  • [Cites] Immunol Invest. 2006;35(2):167-79 [16698675.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2006 Sep;15(9):1641-6 [16985025.001]
  • [Cites] Anticancer Res. 2006 Nov-Dec;26(6C):4721-8 [17214332.001]
  • [Cites] Cancer Lett. 2007 Apr 28;249(1):61-79 [17275179.001]
  • [Cites] Cancer. 2007 Jul 15;110(2):297-308 [17569106.001]
  • [Cites] Gynecol Oncol. 2007 Oct;107(1):58-65 [17659325.001]
  • [Cites] Dis Markers. 2007;23(5-6):419-31 [18057525.001]
  • [Cites] Clin Cancer Res. 2008 Feb 15;14(4):1065-72 [18258665.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Aug;17(8):1880-3 [18708375.001]
  • [Cites] J Surg Oncol. 1990 Jun;44(2):97-9 [2355747.001]
  • [Cites] Med Oncol. 2008;25(3):279-83 [18071928.001]
  • [Cites] Gynecol Oncol. 2009 Jan;112(1):47-54 [19007974.001]
  • [Cites] Cytokine. 2009 Jan;45(1):44-9 [19058974.001]
  • [Cites] Eur Cytokine Netw. 2009 Mar;20(1):21-6 [19318317.001]
  • [CommentIn] J Clin Oncol. 2010 May 1;28(13):2128-30 [20368556.001]
  • (PMID = 20368574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA098642; United States / NCI NIH HHS / CA / CA105009; United States / NCI NIH HHS / CA / R01 CA108990; United States / NCI NIH HHS / CA / U01 CA086381; United States / NCI NIH HHS / CA / P50 CA105009; United States / NCI NIH HHS / CA / P50 CA083639; United States / NCI NIH HHS / CA / CA086381
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Validation Studies
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-125 Antigen; 0 / Carcinoembryonic Antigen; 0 / DEFB126 protein, human; 0 / Epididymal Secretory Proteins; 0 / Vascular Cell Adhesion Molecule-1; 0 / beta-Defensins
  • [Other-IDs] NLM/ PMC2860434
  •  go-up   go-down


81. Da Ines D, Petitcolin V, Lannareix V, Montoriol P, Joubert Zakeyh J, Boyer L, Garcier J: [Liver capsule retraction adjacent to a circumscribed liver lesion: review of 26 cases with histological confirmation]. J Radiol; 2009 Sep;90(9 Pt 1):1067-74
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To review the histological features of 26 circumscribed liver lesions associated with liver capsule retraction and discuss the differential diagnosis while evaluating for the presence of fibrous stromal reaction.
  • RESULTS: Twenty-one patients had benign or malignant liver tumors and 5 patients had confluent hepatic fibrosis.
  • Twenty of 21 liver tumors were malignant (95.2%): 3 intra-hepatic cholangiocarcinoma, 17 cases of metastatic disease including colorectal carcinoma (n=8), bronchogenic carcinoma (n=1), pancreatic carcinoma (n=4), esophageal carcinoma (n=1), breast carcinoma (n=1), gallbladder carcinoma (1) and endocrine neoplasm of the pancreas (n=1), and 1 case of liver sclerosing angioma (n=1).
  • In keeping with previous reports, metastases were frequently the cause and intrahepatic cholangiocarcinoma was the most frequent primary tumor.
  • [MeSH-major] Liver Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Radiol. 2009 Sep;90(9 Pt 1):1019-20 [19752803.001]
  • (PMID = 19752810.001).
  • [ISSN] 0221-0363
  • [Journal-full-title] Journal de radiologie
  • [ISO-abbreviation] J Radiol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


82. Sasaki A, Nitta H, Otsuka K, Takahara T, Nishizuka S, Wakabayashi G: Ten-year experience of totally laparoscopic liver resection in a single institution. Br J Surg; 2009 Mar;96(3):274-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Between May 1997 and April 2008, 82 patients underwent TLLR for hepatocellular carcinoma (HCC) (37 patients), liver metastases (39) and benign liver lesions (six).
  • Nine patients underwent simultaneous laparoscopic resection of colorectal primary cancer and synchronous liver metastases.
  • Median tumour size and surgical margin were 25 (range 15-85) and 6 (range 0-40) mm respectively.
  • The overall 5-year survival rate after surgery for HCC and colorectal metastases was 53 and 64 per cent respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Laparoscopy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Complications / etiology. Length of Stay. Liver Diseases / surgery. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications / etiology. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224518.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


83. Platell C: Transanal endoscopic microsurgery. ANZ J Surg; 2009 Apr;79(4):275-80
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transanal endoscopic microsurgery (TEM) is a minimally invasive surgical technique that was developed more than two decades ago to manage distal colorectal neoplasias.
  • The median neoplasia area was 12 cm(2) (IQR, 6-25 cm(2)) and the median height above the anal verge was 9 cm (IQR, 3-17 cm).
  • During a median follow up of 4.2 years (IQR, 2.6-6.2 years), the 5-year cumulative incidence for local recurrence for benign pathology was 3.1% (95% confidence interval (CI): 1.2-6.7%, n = 180) and for cancers managed primarily by TEM excision it was 8.5% (95%CI: 1.4-23.9%, n = 36).
  • TEM is an excellent treatment modality for benign rectal neoplasias of any size, and in any location.
  • [MeSH-major] Adenocarcinoma / surgery. Adenoma / surgery. Carcinoma in Situ / surgery. Colonoscopy / statistics & numerical data. Rectal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal. Endoscopy, Digestive System. Female. Humans. Male. Microsurgery. Middle Aged. Morbidity. Neoplasm Recurrence, Local / epidemiology. Prospective Studies. Survival Analysis

  • MedlinePlus Health Information. consumer health - Colonoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19432714.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


84. Zhou X, Shang JQ, Zhou JN: [Transsacral local wide resection for mid-lower rectal tumors]. Zhonghua Wei Chang Wai Ke Za Zhi; 2009 Jan;12(1):44-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Transsacral local wide resection for mid-lower rectal tumors].
  • OBJECTIVE: To evaluate the efficacy of transsacral local wide resection for mid-lower rectal tumors.
  • METHODS: Clinical data of 133 patients undergone transsacral local wide resection for mid-lower rectal tumors between September 1994 and September 2005 were analyzed retrospectively.
  • Postoperative diagnosis was adenoma in 28 patients, hyperplastic polyp in 3 patients, carcinoid in 8 patients, gastrointestinal stromal tumor in 1 patient,adenoma with intra-mucosal carcinogenesis in 29 patients and adenocarcinoma invading into submucosa in 64 patients.
  • CONCLUSION: Transsacral local wide resection is simple and safe for mid-lower rectal tumors, which is an appropriate procedure for mid-lower rectal benign tumor and can serve as a sphincter-saving operation for selected T(1) lower rectal carcinoma.
  • [MeSH-major] Rectal Neoplasms / surgery. Sacrococcygeal Region / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145503.001).
  • [ISSN] 1671-0274
  • [Journal-full-title] Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  • [ISO-abbreviation] Zhonghua Wei Chang Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


85. Buell JF, Thomas MT, Rudich S, Marvin M, Nagubandi R, Ravindra KV, Brock G, McMasters KM: Experience with more than 500 minimally invasive hepatic procedures. Ann Surg; 2008 Sep;248(3):475-86
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: We retrospectively reviewed all patients who underwent a minimally invasive procedure for the management of hepatic tumors between January 2001 and April 2008.
  • To compare the various forms of surgery, we analyzed the incidence of complications, tumor recurrence, mortality, and cost.
  • The representative tumor histologies were: hepatocellular carcinoma (HCC; N = 210), colorectal carcinoma (N = 40), miscellaneous liver metastases (N = 42), biliary cancer (N = 20), and benign tumors (N = 176).
  • Our present data are equivalent or superior to those encountered in any large open series.
  • This series confirmed excellent interim survival rates after laparoscopic HR and superiority over RFA in the treatment of cancer, with significantly lower local tumor recurrence rate.
  • [MeSH-major] Hepatectomy / statistics & numerical data. Liver Neoplasms / surgery. Minimally Invasive Surgical Procedures / statistics & numerical data
  • [MeSH-minor] Catheter Ablation / statistics & numerical data. Humans. Laparoscopy / statistics & numerical data. Neoplasm Recurrence, Local / epidemiology. Retrospective Studies. Ultrasonography / statistics & numerical data

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Surg. 2009 Jun;249(6):1064-5; author reply 1065-6 [19474661.001]
  • (PMID = 18791368.001).
  • [ISSN] 1528-1140
  • [Journal-full-title] Annals of surgery
  • [ISO-abbreviation] Ann. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Abouzied MM, Crawford ES, Nabi HA: 18F-FDG imaging: pitfalls and artifacts. J Nucl Med Technol; 2005 Sep;33(3):145-55; quiz 162-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 18F-FDG PET is emerging as a useful tool in the staging and restaging of many malignant neoplasms, such as lymphoma, lung cancer, colorectal cancer, head and neck cancer, breast cancer, and melanoma.
  • To accurately interpret 18F-FDG findings one must be familiar with the normal physiologic distribution of the tracer, frequently encountered physiologic variants, and benign pathologic causes of 18F-FDG uptake that can be confused with a malignant neoplasm.
  • The objectives of this article are to (a) describe the mechanism of 18F-FDG uptake, (b) list the patient preparation and pertinent patient history before 18F-FDG imaging, (c) describe the whole-body physiologic distribution of 18F-FDG, (d) list and discuss normal physiologic variants, and (e) list and discuss benign pathologic causes of 18F-FDG uptake.
  • [MeSH-major] Artifacts. Diagnostic Errors / prevention & control. Fluorodeoxyglucose F18 / pharmacokinetics. Neoplasms / metabolism. Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145222.001).
  • [ISSN] 0091-4916
  • [Journal-full-title] Journal of nuclear medicine technology
  • [ISO-abbreviation] J Nucl Med Technol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 48
  •  go-up   go-down


87. Lee JH, Ross WA, Davila R, Chang G, Lin E, Dekovich A, Davila M: Self-expandable metal stents (SEMS) can serve as a bridge to surgery or as a definitive therapy in patients with an advanced stage of cancer: clinical experience of a tertiary cancer center. Dig Dis Sci; 2010 Dec;55(12):3530-6
MedlinePlus Health Information. consumer health - Intestinal Obstruction.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Self-expandable metal stents (SEMS) can be used to relieve benign and malignant colorectal obstruction.
  • AIMS: The aim of this study was to determine the outcomes of SEMS for malignant colorectal obstruction.
  • Cancer types included: 28 colorectal, and 18 metastatic cancers.
  • CONCLUSIONS: Placement of SEMS for the treatment of colorectal obstruction is feasible and safe.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colon, Sigmoid / pathology. Colorectal Neoplasms / complications. Colorectal Neoplasms / pathology. Constriction, Pathologic. Female. Fluoroscopy. Foreign-Body Migration / epidemiology. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prosthesis Design. Retrospective Studies. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20721627.001).
  • [ISSN] 1573-2568
  • [Journal-full-title] Digestive diseases and sciences
  • [ISO-abbreviation] Dig. Dis. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


88. Sheng SL, Huang G, Yu B, Qin WX: Clinical significance and prognostic value of serum Dickkopf-1 concentrations in patients with lung cancer. Clin Chem; 2009 Sep;55(9):1656-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • By use of this method, we investigated the serum concentrations of DKK1 in 592 patients with malignancies, 72 patients with benign lung disease, and 120 healthy controls.
  • RESULTS: Serum DKK1 concentrations were significantly higher in patients with lung cancer than in patients with other malignant tumors or benign lung diseases and healthy controls.
  • Serum concentrations of DKK1 were decreased significantly in groups of patients with gastric cancer, colorectal cancer, ovarian cancer, and cervical adenocarcinoma compared with healthy controls.
  • DKK1 concentrations increased with stage, tumor class, and presence of lymph node and distant metastases, regardless of histology and patient age and sex.
  • Increasing concentrations of DKK1were significantly associated with tumor progression and decreased survival in patients with lung cancer. .
  • [MeSH-major] Biomarkers, Tumor / blood. Fluoroimmunoassay / methods. Intercellular Signaling Peptides and Proteins / blood. Lung Neoplasms / blood
  • [MeSH-minor] Aged. Calibration. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Neoplasm Staging. Prognosis. Survival Rate

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19628661.001).
  • [ISSN] 1530-8561
  • [Journal-full-title] Clinical chemistry
  • [ISO-abbreviation] Clin. Chem.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  •  go-up   go-down


89. Alsaad KO, Serra S, Schmitt A, Perren A, Chetty R: Cytokeratins 7 and 20 immunoexpression profile in goblet cell and classical carcinoids of appendix. Endocr Pathol; 2007;18(1):16-22
MedlinePlus Health Information. consumer health - Carcinoid Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Goblet cell carcinoid (GCC) of the vermiform appendix is an uncommon neoplasm and its histogenesis is controversial.
  • Little is known about the immunohistochemical expression of cytokeratins 7 (CK7) and 20 (CK20) in appendiceal neuroendocrine tumors.
  • The tumors were also evaluated for Ki-67 proliferation index, mitotic activity, tumor necrosis, extracellular pools of mucin, obvious intestinal type adenocarcinomatous foci, angiolymphatic permeation, perineural/neural infiltration, and the depth of invasion of the appendix wall.
  • Immunohistochemically, all 17 (100%) of GCC exhibited strong and diffuse immunopositivity for CK20, whereas expression of CK7 was present in 12 cases (70.5%), ranging from 5 to 50% of tumor cells being labeled.
  • On the other hand, 25 cases of classical carcinoid tumors were consistently negative for CK7; however, 4 cases (16%) showed immunolabeling for CK20 in 25-50% of the tumor cells.
  • In addition, GCC shows the same CK7/CK20 immunoexpression as colorectal adenocarcinoma.
  • Goblet cell carcinoid should be regarded as a crypt cell or an amphicrine carcinoma rather than a variant of carcinoid tumor, a lesion that has benign connotations.
  • [MeSH-major] Appendiceal Neoplasms / metabolism. Carcinoid Tumor / metabolism. Goblet Cells / metabolism. Keratin-20 / metabolism. Keratin-7 / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Cell Proliferation. Female. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male. Middle Aged. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17652796.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Keratin-20; 0 / Keratin-7; 0 / Ki-67 Antigen
  •  go-up   go-down


90. Olgac S, Hutchinson B, Tickoo SK, Reuter VE: Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma. Mod Pathol; 2006 Feb;19(2):218-24
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alpha-methylacyl-CoA racemase as a marker in the differential diagnosis of metanephric adenoma.
  • Metanephric adenoma (MA), a well-described renal neoplasm, usually behaves in a benign fashion.
  • It may have areas that are morphologically similar to papillary renal cell carcinoma (RCC) type, or epithelial (tubular predominant) type Wilms' tumor.
  • Alpha-methylacyl-CoA racemase (AMACR), a molecular marker for prostate carcinoma, has subsequently been found to be overexpressed in breast, colorectal and ovarian cancers, among others.
  • Recent microarray analysis of renal tumors has shown an increase of AMACR mRNA levels in papillary RCC but not in other subtypes.
  • We investigated the utility of immunohistochemical staining for AMACR, cytokeratin 7(CK7), CD57 and WT1 to differentiate between the above-mentioned three neoplasms.
  • Immunohistochemical stains were performed on paraffin-embedded tissue sections from 25 papillary RCC, 10 MAs and eight Wilms' tumors.
  • AMACR was positive in one (10%) of 10 MAs and 24 (96%) of 25 papillary RCC, while it was negative in all Wilms' tumors.
  • CK7 was positive in 20 of 25 papillary RCCs, focally positive in one Wilms' tumor and was negative in all MAs.
  • CD57 was positive in all six MAs that were stained, focally positive in one of 25 papillary RCC and one of eight Wilms' tumors.
  • WT1 was positive in seven of 10 MAs, three of 25 papillary RCCs and all eight Wilms' tumors.
  • In conclusion, diffuse and strong immunoreactivity for AMACR may be useful in differentiating papillary RCC from MA but a panel which includes AMACR, CK7 and CD57 is better in this differential diagnosis.
  • AMACR is not helpful in differentiating MA from Wilms' tumor, but CD57 is helpful in this differential diagnosis.
  • WT1 may be useful in separating Wilms' tumor from MA and papillary RCC but is not helpful in differentiating MA from papillary RCC.
  • [MeSH-major] Adenoma / pathology. Biomarkers, Tumor / analysis. Kidney Neoplasms / pathology. Racemases and Epimerases / analysis
  • [MeSH-minor] Antigens, CD57 / analysis. Carcinoma, Papillary / enzymology. Carcinoma, Papillary / pathology. Carcinoma, Renal Cell / enzymology. Carcinoma, Renal Cell / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratin-7. Keratins / analysis. WT1 Proteins / analysis. Wilms Tumor / enzymology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16424894.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD57; 0 / Biomarkers, Tumor; 0 / KRT7 protein, human; 0 / Keratin-7; 0 / WT1 Proteins; 68238-35-7 / Keratins; EC 5.1.- / Racemases and Epimerases; EC 5.1.99.4 / alpha-methylacyl-CoA racemase
  •  go-up   go-down


91. Colliver DW, Crawford NP, Eichenberger MR, Zacharius W, Petras RE, Stromberg AJ, Galandiuk S: Molecular profiling of ulcerative colitis-associated neoplastic progression. Exp Mol Pathol; 2006 Feb;80(1):1-10
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fundamental differences exist between ulcerative colitis (UC)-associated and sporadic forms of colorectal cancer, including preexisting inflammation, type of dysplasia, and timing of molecular events in carcinogenesis.
  • Transcriptional alterations that occur in UC-associated neoplasia in the progression from normal mucosa through dysplastic epithelium to invasive cancer have not been described.
  • We used Affymetrix U95Av2 microarrays to assess differential gene expression in the neoplastic progression of UC tissue from the colonic mucosa of individuals with benign UC, UC-dysplasia-associated lesions or masses, and UC adenocarcinoma.
  • Based on comparisons with previous studies on sporadic colorectal carcinoma, several similarities were found.
  • There were, however, important differences that suggest that different molecular events may occur in the development of UC-associated neoplasia.
  • Identification of these genes as potential clinical biomarkers may lead to improved early disease diagnosis.
  • [MeSH-major] Adenocarcinoma / metabolism. Colitis, Ulcerative / metabolism. Colorectal Neoplasms / metabolism. Gene Expression Profiling. Intestinal Mucosa / metabolism. Precancerous Conditions / metabolism
  • [MeSH-minor] Gene Expression Regulation, Neoplastic. Humans. Neoplasm Proteins / metabolism. Oligonucleotide Array Sequence Analysis

  • Genetic Alliance. consumer health - Ulcerative Colitis.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16277983.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins
  •  go-up   go-down


92. Zammit M, Jenkins JT, Urie A, O'Dwyer PJ, Molloy RG: A technically difficult endorectal ultrasound is more likely to be inaccurate. Colorectal Dis; 2005 Sep;7(5):486-91

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Specific reasons for inaccuracy identified in this group were: inflammatory lymph nodes (from a tumour associated abscess and a colovesical fistula) and deep biopsy causing a submucosal defect with intramural haemorrhage in benign lesions (2 cases).
  • In the remaining 39 (33.3%), the following problems were encountered: stenotic lesions (23), patient discomfort (8), poor bowel preparation (6), and scarring from previous surgery (2).
  • [MeSH-major] Endosonography / methods. Rectal Neoplasms / ultrasonography
  • [MeSH-minor] Aged. Aged, 80 and over. Chi-Square Distribution. Diagnostic Errors. Female. Humans. Male. Middle Aged. Neoplasm Staging / methods. Prospective Studies. Sensitivity and Specificity. Statistics, Nonparametric

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16108886.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


93. Wiese D, Saha S, Yestrepsky B, Korant A, Sirop S: A prospective study of false-positive diagnosis of micrometastatic cells in the sentinel lymph nodes in colorectal cancer. Ann Surg Oncol; 2009 Aug;16(8):2166-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A prospective study of false-positive diagnosis of micrometastatic cells in the sentinel lymph nodes in colorectal cancer.
  • False-positive SLNs occur in breast cancer due to mechanical transport of cells during mapping procedures, or to pre-existing benign cellular inclusions.
  • Our prospective study evaluated whether colorectal mapping procedures alone caused false positives.
  • Ninety of the pts underwent a second mapping in normal bowel away from the primary tumor.
  • The first 1-5 blue nodes near the primary tumor were marked as SLNs; those near the second injection site were marked as nontumor SLNs (nt-SLNs).
  • RESULTS: Of 314 pts, 30 had benign tumor and 284 had invasive cancer.
  • Forty-six of the 274 pts (16.8%) had low-volume metastasis in 57 SLNs: 31 pts (11.3%) had 38 SLNs with micrometastasis (>0.2 mm, <or=2 mm), while 15 pts (5.5%) had 19 SLNs with isolated tumor cells (<or=0.2 mm).
  • For 100 pts with second SLNM (70/90 pts successfully mapped with 102 nt-SLNs), or with SLNM of benign pathology (30/30 pts successfully mapped with 88 SLNs), there were no false positives in any of 190 nodes (P < 0.001).
  • CONCLUSION: No false positives due to mechanical transport of cells or to benign cellular inclusions were identified in 190 lymph nodes from 100 patients with SLNM in benign bowel.
  • [MeSH-major] Colorectal Neoplasms / secondary. Hepatectomy. Lymph Nodes / pathology. Sentinel Lymph Node Biopsy
  • [MeSH-minor] False Positive Reactions. Humans. Keratins / metabolism. Lymphatic Metastasis. Neoplasm Staging. Prognosis. Prospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19412630.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 68238-35-7 / Keratins
  •  go-up   go-down


94. Chzhao AV, Kovalenko IuA, Chugunov AO, Novruzbekov MS: [Volume of surgical resection by liver focal lesions]. Khirurgiia (Mosk); 2010;(5):15-20
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Volume resection by malignant and benign liver lesions was defined, depending on size, localization, number of foci and functional liver reserve.
  • Postoperative lethality of patients with colorectal cancer metastases was 4.3%.
  • Method of surgical treatment depended directly on the tumor stage.
  • Overall and disease-free survival by colorectal cancer metastases was 35.1 and 22.4%, respectively.
  • [MeSH-major] Hepatectomy / methods. Liver Neoplasms / mortality. Liver Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Colorectal Neoplasms / mortality. Colorectal Neoplasms / secondary. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Metastasis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20559205.001).
  • [ISSN] 0023-1207
  • [Journal-full-title] Khirurgiia
  • [ISO-abbreviation] Khirurgiia (Mosk)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


95. Remzi FH, Kirat HT, Geisler DP: Laparoscopic single-port colectomy for sigmoid cancer. Tech Coloproctol; 2010 Sep;14(3):253-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Laparoscopic single-port sigmoid colectomy through a 3-cm umbilical incision was performed on a patient with a diagnosis of sigmoid cancer.
  • Colonoscopy performed 1 year after surgery showed no neoplasm or polyp identified.
  • CONCLUSION: Single-port laparoscopic surgery may allow common benign procedures via an incision in the umbilicus.
  • It can also be performed with good surgical and oncologic results in selected patients with a colorectal cancer.
  • [MeSH-major] Laparoscopy / methods. Sigmoid Neoplasms / pathology. Sigmoid Neoplasms / surgery. Umbilicus / surgery
  • [MeSH-minor] Female. Follow-Up Studies. Humans. Length of Stay. Middle Aged. Neoplasm Staging. Pain, Postoperative. Sigmoidoscopy / methods. Treatment Outcome

  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19953288.001).
  • [ISSN] 1128-045X
  • [Journal-full-title] Techniques in coloproctology
  • [ISO-abbreviation] Tech Coloproctol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


96. Szajda SD, Jankowska A, Zwierz K: Carbohydrate markers in colon carcinoma. Dis Markers; 2008;25(4-5):233-42

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Spontaneously mutated multiple oncogenes and/or tumor suppressor genes in colon epithelial cell and its progeny, may cause proliferation out of control and create benign colon neoplasm (colon polyp).
  • If additional mutations involve genes responsible for cell adhesion and movement, aberrant epithelial cells may become malignant (colon cancer) and invade surrounding and remote tissues, creating secondary tumors called metastases.
  • Incidence of colorectal cancer dramatically increases at 50-65 year of age.
  • In Europe in 2006 colorectal cancer consisted 12.9% of all cancers and caused 207,400 deaths.
  • To laboratory detection and monitoring of colon cancer are used tumor markers.
  • Tumor markers are substances produced by the body in response to cancer, or by cancer tissue itself.
  • A glycobiological approach to diagnosis and treatment of colorectal cancer should be directed to detection changes in glycosylation accompanying every step of colon cancer progression, and correlation between changes in glycosylation and tumor progression.
  • [MeSH-major] Carbohydrates / chemistry. Carcinoma / metabolism. Colonic Neoplasms / metabolism
  • [MeSH-minor] Aged. Cadherins / chemistry. Cell Adhesion. Disease Progression. Epithelial Cells / metabolism. Glycoproteins / chemistry. Glycoproteins / metabolism. Humans. Middle Aged. Mucins / metabolism. Neoplasm Invasiveness. Neoplasm Metastasis. Polysaccharides / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126967.001).
  • [ISSN] 0278-0240
  • [Journal-full-title] Disease markers
  • [ISO-abbreviation] Dis. Markers
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Cadherins; 0 / Carbohydrates; 0 / Glycoproteins; 0 / Mucins; 0 / Polysaccharides
  • [Number-of-references] 79
  • [Other-IDs] NLM/ PMC3827819
  •  go-up   go-down


97. Speake D, Lees N, McMahon RF, Hill J: Who should be followed up after transanal endoscopic resection of rectal tumours? Colorectal Dis; 2008 May;10(4):330-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Of the 117 procedures performed, 80 were for benign disease and 37 for malignancy.
  • Within the benign group 39 (49%) resections were intact with clear surgical resection margins and yielded zero recurrences; 22 (27%) resections were macroscopically intact with microscopically involved surgical resection margin and yielded two recurrences; and 19 (24%) resections were piecemeal and yielded eight recurrences.
  • CONCLUSION: For benign rectal neoplasms, resection of an intact specimen with histologically clear surgical resection margins was associated with no observed mucosal recurrence.
  • [MeSH-major] Adenoma. Carcinoma. Endoscopy, Gastrointestinal / methods. Microsurgery / methods. Neoplasm Recurrence, Local / prevention & control. Rectal Neoplasms
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Anal Canal / surgery. Case-Control Studies. Disease-Free Survival. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18190616.001).
  • [ISSN] 1463-1318
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


98. Schmidt MB, Engel UH, Mogensen AM, Petersen LN, Bülow S, Wied U, Holck S, Danish Colorectal Cancer Group: [Resection time and number of detected colorectal lymph nodes in resection specimens with carcinoma]. Ugeskr Laeger; 2009 Aug 24;171(35):2458-62
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resection time and number of detected colorectal lymph nodes in resection specimens with carcinoma].
  • INTRODUCTION: The number of identified lymph nodes (LNs) is an essential element in the pathologist's rapport on colorectal resection specimens with carcinoma (CRSC).
  • Provided this careful analysis failed to produce 12 LNs and all detected LNs were benign (pNx), the specimen was re-sampled for an additional 15-minute period.
  • [MeSH-major] Colorectal Neoplasms / pathology. Lymph Node Excision. Lymph Nodes / pathology. Lymphatic Metastasis / pathology
  • [MeSH-minor] Humans. Neoplasm Staging. Prospective Studies. Specimen Handling. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19732530.001).
  • [ISSN] 1603-6824
  • [Journal-full-title] Ugeskrift for laeger
  • [ISO-abbreviation] Ugeskr. Laeg.
  • [Language] dan
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


99. Wernicke AG, Dicker AP, Whiton M, Ivanidze J, Hyslop T, Hammond EH, Perry A, Andrews DW, Kenyon L: Assessment of Epidermal Growth Factor Receptor (EGFR) expression in human meningioma. Radiat Oncol; 2010;5:46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This study explores whether meningioma expresses epidermal growth factor receptor (EGFR) and determines if there is a correlation between the WHO grade of this tumor and the degree of EGFR expression.
  • RESULTS: Eighty-five samples of meningioma were classified in accordance with World Health Organization (WHO) criteria: benign 57/85 (67%), atypical 23/85 (27%), and malignant 5/85 (6%).
  • A significant association was determined when the benign and the atypical samples were compared to the malignant with respect to the SP (p = 0.009).
  • While there was a range of the IHS for the benign and the atypical histologic subtypes, malignant tumors exhibited the lowest score and were statistically different from the benign and the atypical specimens (p < 0.001).
  • EGFR expression is greatest in benign meningiomas and may serve a potential target for therapeutic intervention with selective EGFR inhibitors.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Humans. Immunoenzyme Techniques. Neoplasm Staging. Prognosis. Tissue Array Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1984 Feb;44(2):753-60 [6318976.001]
  • [Cites] Curr Pharm Des. 2007;13(33):3358-67 [18045190.001]
  • [Cites] Surg Neurol. 1986 Mar;25(3):233-42 [3945904.001]
  • [Cites] Cancer Res. 1986 May;46(5):2545-50 [3697993.001]
  • [Cites] Acta Neurochir (Wien). 1986;83(1-2):62-6 [3492089.001]
  • [Cites] Cancer Res. 1987 Apr 15;47(8):2172-6 [3493842.001]
  • [Cites] Neurosurgery. 1987 Apr;20(4):525-8 [3587542.001]
  • [Cites] Pol J Pathol. 1998;49(3):145-9 [9810172.001]
  • [Cites] J Neuropathol Exp Neurol. 1999 Jul;58(7):697-701 [10411339.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] N Engl J Med. 2005 Oct 20;353(16):1659-72 [16236737.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] J Neurosurg. 2007 Jun;106(6):1034-40 [17564176.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] Cancer. 1988 Nov 15;62(10):2139-44 [3052782.001]
  • [Cites] Cancer. 1990 Jul 1;66(1):152-5 [2354402.001]
  • [Cites] Cancer Invest. 1991;9(5):553-62 [1933488.001]
  • [Cites] J Endocrinol Invest. 1992 Jan;15(1):31-7 [1560188.001]
  • [Cites] Br J Neurosurg. 1993;7(2):197-9 [8388222.001]
  • [Cites] Surg Gynecol Obstet. 1993 Nov;177(5):488-96 [8211601.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] Hum Pathol. 1994 Feb;25(2):146-53 [8119714.001]
  • [Cites] Crit Rev Oncol Hematol. 1995 Jul;19(3):183-232 [7612182.001]
  • [Cites] J Neurol. 1995 Oct;242(10):683-8 [8568531.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1996 Mar 1;34(4):809-15 [8598357.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1284-92 [8826952.001]
  • [Cites] Br J Cancer. 1996 Oct;74(8):1253-7 [8883413.001]
  • [Cites] Anticancer Res. 1997 Jan-Feb;17(1B):769-74 [9066618.001]
  • [Cites] Neuropeptides. 1997 Jun;31(3):217-25 [9243517.001]
  • [Cites] J Neurosurg. 1997 Aug;87(2):315-23 [9254099.001]
  • [Cites] Acta Oncol. 1998;37(3):285-9 [9677101.001]
  • [Cites] Cancer Res. 2002 Dec 15;62(24):7350-6 [12499279.001]
  • [Cites] Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2002 Aug;24(4):427-9 [12905669.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):135-42 [15148612.001]
  • [Cites] J Neurosci Res. 1982;8(2-3):491-507 [6296418.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Lung Cancer. 2007 Aug;57 Suppl 2:S18-23 [17686441.001]
  • [Cites] Expert Opin Pharmacother. 2007 Oct;8(15):2579-92 [17931092.001]
  • [Cites] Clin Colorectal Cancer. 2007 Oct;6 Suppl 2:S42-6 [18021486.001]
  • [Cites] Drugs. 2007;67(17):2585-607 [18034592.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Nov;7(7):650-65 [18045070.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • (PMID = 20509969.001).
  • [ISSN] 1748-717X
  • [Journal-full-title] Radiation oncology (London, England)
  • [ISO-abbreviation] Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor
  • [Other-IDs] NLM/ PMC2890616
  •  go-up   go-down


100. Wang S, Bromley E, Xu L, Chen JC, Keltner L: Talaporfin sodium. Expert Opin Pharmacother; 2010 Jan;11(1):133-40
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Systemic antitumor effects mediated by CD8(+) T cells have been demonstrated in preclinical studies, providing a mechanism for distant response of tumors noted in clinical trials.
  • Phase I and II studies in solid tumors have shown tumor regression in patients refractory to other therapies.
  • Phase III pivotal studies against hepatocellular carcinoma as monotherapy and liver-metastatic colorectal cancer in combination with chemotherapy are ongoing.
  • Talaporfin sodium is also in studies in men with symptomatic benign prostatic hyperplasia.
  • WHAT THE READER WILL GAIN: Talaporfin sodium has a broad safety profile and a mode of action that could affect growth in treated and untreated tumors.
  • [MeSH-major] Colorectal Neoplasms / drug therapy. Liver Neoplasms / drug therapy. Porphyrins / therapeutic use
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cancer Vaccines / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Clinical Trials, Phase III as Topic. Combined Modality Therapy / methods. Humans. Japan / epidemiology. Male. Neoplasm Staging. Neoplasms. Oxides / metabolism

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001435.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Cancer Vaccines; 0 / Oxides; 0 / Porphyrins; P4ROX5ELT2 / Talaporfin
  • [Number-of-references] 29
  •  go-up   go-down






Advertisement